DownloadHi-Res Photo

Lakshmanan Krishnamurti, MD

Professor of Pediatrics (Hematology/Oncology); Chief, Pediatric Hematology and Oncology

Research & Publications
Biography
News

Research Summary

Extensive Research Description

My main areas of interest are clinical research in hemoglobinopathies, hematopoietic stem cell transplantation and systems approach to the delivery of care including newborn screening, international outreach, community outreach and the use of informatics to enhance care. I am the PI on and NHLBI funded R34 for BMT for adults with sickle cell disease and on two separate PCORI-funded projects, one developing a decision aid for treatment of patients with sickle cell disease with hydroxyurea and stem cell transplant and the second evaluating improvement of adherence to hydroxyurea therapy directly observed via cell phone camera.

Coauthors

Selected Publications

Distributional Cost-Effectiveness of Equity-Enhancing Gene Therapy in Sickle Cell Disease in the United States.Goshua G, Calhoun C, Ito S, James L, Luviano A, Krishnamurti L, Pandya A. Distributional Cost-Effectiveness of Equity-Enhancing Gene Therapy in Sickle Cell Disease in the United States. Annals Of Internal Medicine 2023, 176: 779-787. PMID: 37247420, PMCID: PMC10370480, DOI: 10.7326/m22-3272.
Female Reproductive Health Outcomes after Hematopoietic Cell Transplantation for Sickle Cell Disease: Is Reduced Intensity Better Than Myeloablative Conditioning?Meacham L, George S, Veludhandi A, Pruett M, Haight A, Arnold S, Elchuri S, Stenger E, Krishnamurti L. Female Reproductive Health Outcomes after Hematopoietic Cell Transplantation for Sickle Cell Disease: Is Reduced Intensity Better Than Myeloablative Conditioning? Transplantation And Cellular Therapy 2023, 29: 531.e1-531.e4. PMID: 37169288, DOI: 10.1016/j.jtct.2023.05.004.
Parental perspective on the risk of infertility and fertility preservation options for children and adolescents with sickle cell disease considering hematopoietic stem cell transplantationSinha C, Meacham L, Bakshi N, Ross D, Krishnamurti L. Parental perspective on the risk of infertility and fertility preservation options for children and adolescents with sickle cell disease considering hematopoietic stem cell transplantation. Pediatric Blood & Cancer 2023, 70: e30276. PMID: 37051746, PMCID: PMC10544372, DOI: 10.1002/pbc.30276.
488 Feasibility of Using the American Time Use Survey to Study the Impact of Sickle Cell Disease and Hematopoietic Cell Transplant on the Daily Lives of Patients and Their Caregivers: A Stellar StudyKhemani K, Stenger E, Arnold S, Bakshi N, Ross D, Smith C, Basu A, Krishnamurti L. 488 Feasibility of Using the American Time Use Survey to Study the Impact of Sickle Cell Disease and Hematopoietic Cell Transplant on the Daily Lives of Patients and Their Caregivers: A Stellar Study. Transplantation And Cellular Therapy 2023, 29: s366. DOI: 10.1016/s2666-6367(23)00556-0.
392 Avascular Necrosis Following Hematopoietic Cell Transplantation for Sickle Cell DiseaseHamidi R, He Z, Deng Y, Flagg A, Shah N, Krishnamurti L. 392 Avascular Necrosis Following Hematopoietic Cell Transplantation for Sickle Cell Disease. Transplantation And Cellular Therapy 2023, 29: s297-s298. DOI: 10.1016/s2666-6367(23)00461-x.
390 Endothelial Complications of Hematopoietic Cell Transplantation for Sickle Cell DiseaseFlagg A, Hamidi R, He Z, Deng Y, Shah N, Krishnamurti L. 390 Endothelial Complications of Hematopoietic Cell Transplantation for Sickle Cell Disease. Transplantation And Cellular Therapy 2023, 29: s296. DOI: 10.1016/s2666-6367(23)00459-1.
384 Vaso-Occlusive Pain Requiring Hospitalization or Treatment Is Rare Following Successful Hematopoietic Cell Transplantation for Sickle Cell DiseaseKrishnamurti L, He Z, Deng Y, Hamidi R, Flagg A, Shah N. 384 Vaso-Occlusive Pain Requiring Hospitalization or Treatment Is Rare Following Successful Hematopoietic Cell Transplantation for Sickle Cell Disease. Transplantation And Cellular Therapy 2023, 29: s291. DOI: 10.1016/s2666-6367(23)00453-0.
379 The Impact of Current Conditioning Regimen, T Cell Depletion and Graft Versus Host Disease Prophylaxis on the Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Sickle Cell DiseaseShah N, Flagg A, Hamidi R, Hugo H, Deng Y, Krishnamurti L. 379 The Impact of Current Conditioning Regimen, T Cell Depletion and Graft Versus Host Disease Prophylaxis on the Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Sickle Cell Disease. Transplantation And Cellular Therapy 2023, 29: s286-s287. DOI: 10.1016/s2666-6367(23)00448-7.
378 Main Reasons for Performing Hematopoietic Cell Transplantation in Patients with Sickle Cell Disease: Evolution over the Last Three DecadesFlagg A, He Z, Deng Y, Hamidi R, Shah N, Krishnamurti L. 378 Main Reasons for Performing Hematopoietic Cell Transplantation in Patients with Sickle Cell Disease: Evolution over the Last Three Decades. Transplantation And Cellular Therapy 2023, 29: s285-s286. DOI: 10.1016/s2666-6367(23)00447-5.
Thrombo-Inflammation in COVID-19 and Sickle Cell Disease: Two Faces of the Same CoinChiang K, Gupta A, Sundd P, Krishnamurti L. Thrombo-Inflammation in COVID-19 and Sickle Cell Disease: Two Faces of the Same Coin. Biomedicines 2023, 11: 338. PMID: 36830874, PMCID: PMC9953430, DOI: 10.3390/biomedicines11020338.
Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell DiseaseEapen M, Brazauskas R, Williams D, Walters M, St Martin A, Jacobs B, Antin J, Bona K, Chaudhury S, Coleman-Cowger V, DiFronzo N, Esrick E, Field J, Fitzhugh C, Kanter J, Kapoor N, Kohn D, Krishnamurti L, London W, Pulsipher M, Talib S, Thompson A, Waller E, Wun T, Horowitz M. Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease. Journal Of Clinical Oncology 2023, 41: 2227-2237. PMID: 36623245, PMCID: PMC10448940, DOI: 10.1200/jco.22.01203.
Feasibility of Using the American Time Use Survey to Study the Impact of Sickle Cell Disease and Hematopoietic Cell Transplant on the Daily Lives of Patients and Their Caregivers: A Stellar StudyKhemani K, Arnold S, Bakshi N, Ross D, Smith C, Basu A, Stenger E, Krishnamurti L. Feasibility of Using the American Time Use Survey to Study the Impact of Sickle Cell Disease and Hematopoietic Cell Transplant on the Daily Lives of Patients and Their Caregivers: A Stellar Study. Blood 2022, 140: 13043-13044. DOI: 10.1182/blood-2022-170685.
Endothelial Complications of Hematopoietic Cell Transplantation for Sickle Cell DiseaseFlagg A, Hamidi R, Deng Y, Shah N, Krishnamurti L, He Z. Endothelial Complications of Hematopoietic Cell Transplantation for Sickle Cell Disease. Blood 2022, 140: 10460-10461. DOI: 10.1182/blood-2022-169107.
Gonadal Hormone Production after Hematopoietic Cell Transplant (HCT) in Patients with Sickle Cell Disease (SCD): A Stellar StudyGeorge S, Veludhandi A, Xiang Y, Stenger E, Arnold S, Mehta A, Schirmer D, Spencer J, Guilcher G, Bhatia M, Abraham A, Gomez-Lobo V, Krishnamurti L, Meacham L. Gonadal Hormone Production after Hematopoietic Cell Transplant (HCT) in Patients with Sickle Cell Disease (SCD): A Stellar Study. Blood 2022, 140: 1391-1392. DOI: 10.1182/blood-2022-168060.
Preliminary Results of Promis Sexual Function and Satisfaction and Perceived Risk for Infertility after Hematopoietic Cell Transplantation for Sickle Cell Disease: A Stellar StudyMeacham L, Veludhandi A, Xiang Y, Stenger E, Arnold S, Mehta A, Pecker L, Hsieh M, Maher J, Krishnamurti L. Preliminary Results of Promis Sexual Function and Satisfaction and Perceived Risk for Infertility after Hematopoietic Cell Transplantation for Sickle Cell Disease: A Stellar Study. Blood 2022, 140: 1397-1398. DOI: 10.1182/blood-2022-163279.
Gene Therapy Equity in Sickle Cell Disease: Distributional Cost-Effectiveness Analysis (DCEA) of Gene Therapy Vs. Standard-of-Care in Patients with Sickle Cell Disease in the United StatesGoshua G, Calhoun C, Cheng V, James L, Luviano A, Krishnamurti L, Pandya A. Gene Therapy Equity in Sickle Cell Disease: Distributional Cost-Effectiveness Analysis (DCEA) of Gene Therapy Vs. Standard-of-Care in Patients with Sickle Cell Disease in the United States. Blood 2022, 140: 1395-1396. DOI: 10.1182/blood-2022-157460.
Multimodal phenotyping and correlates of pain following hematopoietic cell transplant in children with sickle cell diseaseBakshi N, Astles R, Chou E, Hurreh A, Sil S, Sinha C, Sanders K, Peddineni M, Gillespie S, Keesari R, Krishnamurti L. Multimodal phenotyping and correlates of pain following hematopoietic cell transplant in children with sickle cell disease. Pediatric Blood & Cancer 2022, 70: e30046-e30046. PMID: 36322607, PMCID: PMC9820671, DOI: 10.1002/pbc.30046.
Long-Term Organ Function After HCT for SCD: A Report From the Sickle Cell Transplant Advocacy and Research AllianceStenger E, Xiang Y, Wetzel M, Gillespie S, Chellapandian D, Shah R, Arnold S, Bhatia M, Chaudhury S, Eckrich M, Kanter J, Kasow K, Krajewski J, Nickel R, Ngwube A, Olson T, Rangarajan H, Wobma H, Guilcher G, Horan J, Krishnamurti L, Shenoy S, Abraham A. Long-Term Organ Function After HCT for SCD: A Report From the Sickle Cell Transplant Advocacy and Research Alliance. Transplantation And Cellular Therapy 2022, 29: 47.e1-47.e10. PMID: 36273784, DOI: 10.1016/j.jtct.2022.10.012.
Enrollment Lessons from a Biological Assignment Study of Marrow Transplantation versus Standard Care for Adolescents and Young Adults with Sickle Cell Disease: Considerations for Future Gene and Cellular Therapy TrialsKrishnamurti L, Neuberg D, Sullivan K, Smith S, Eapen M, Walters M. Enrollment Lessons from a Biological Assignment Study of Marrow Transplantation versus Standard Care for Adolescents and Young Adults with Sickle Cell Disease: Considerations for Future Gene and Cellular Therapy Trials. Transplantation And Cellular Therapy 2022, 29: 217-221. PMID: 36270432, PMCID: PMC10539686, DOI: 10.1016/j.jtct.2022.10.008.
Decision-making about gene therapy in transfusion dependent thalassemiaQuarmyne M, Ross D, Sinha C, Bakshi N, Boudreaux J, Krishnamurti L. Decision-making about gene therapy in transfusion dependent thalassemia. BMC Pediatrics 2022, 22: 536. PMID: 36085025, PMCID: PMC9461218, DOI: 10.1186/s12887-022-03598-3.
Sickle Cell Transplantation Evaluation of Long-term and Late Effects Registry (STELLAR) to Compare Long-term Outcomes After Hematopoietic Cell Transplantation to Those in Siblings Without Sickle Cell Disease and in Nontransplanted Individuals With Sickle Cell Disease: Design and Feasibility StudyKrishnamurti L, Arnold S, Haight A, Abraham A, Guilcher G, John T, Bakshi N, Shenoy S, Syrjala K, Martin P, Chaudhury S, Eames G, Olowoselu O, Hsieh M, De La Fuente J, Kasow K, Stenger E, Mertens A, El-Rassi F, Lane P, Shaw B, Meacham L, Archer D. Sickle Cell Transplantation Evaluation of Long-term and Late Effects Registry (STELLAR) to Compare Long-term Outcomes After Hematopoietic Cell Transplantation to Those in Siblings Without Sickle Cell Disease and in Nontransplanted Individuals With Sickle Cell Disease: Design and Feasibility Study. JMIR Research Protocols 2022, 11: e36780. PMID: 35793124, PMCID: PMC9301564, DOI: 10.2196/36780.
Associated comorbidities, healthcare utilization & mortality in hospitalized patients with haemophilia in the United States: Contemporary nationally representative estimatesDay J, Takemoto C, Sharathkumar A, Makhani S, Gupta A, Bitner S, Josephson C, Bloch E, Tobian A, Krishnamurti L, Goel R. Associated comorbidities, healthcare utilization & mortality in hospitalized patients with haemophilia in the United States: Contemporary nationally representative estimates. Haemophilia 2022, 28: 532-541. PMID: 35412659, PMCID: PMC9540439, DOI: 10.1111/hae.14557.
Effects of Music Therapy on Quality of Life in Adults with Sickle Cell Disease (MUSIQOLS): A Mixed Methods Feasibility Study [Erratum]Rodgers-Melnick S, Lin L, Gam K, Souza de Santana Carvalho E, Jenerette C, Rowland D, Little J, Dusek J, Bakshi N, Krishnamurti L. Effects of Music Therapy on Quality of Life in Adults with Sickle Cell Disease (MUSIQOLS): A Mixed Methods Feasibility Study [Erratum]. Journal Of Pain Research 2022, 15: 1123-1124. PMID: 35469252, PMCID: PMC9034844, DOI: 10.2147/jpr.s370799.
280 Sustained Improvements in Patient Reported Quality of Life up to 24 Months Post-Treatment with LentiGlobin for Sickle Cell Disease (bb1111) Gene TherapyWalters M, Tisdale J, Mapara M, Krishnamurti L, Kwiatkowski J, Aygun B, Kasow K, Rifkin-Zenenberg S, Jaroscak J, Garbinsky D, Chirila C, Gallagher M, Zhang X, Ho P, Thompson A, Kanter J. 280 Sustained Improvements in Patient Reported Quality of Life up to 24 Months Post-Treatment with LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy. Transplantation And Cellular Therapy 2022, 28: s222-s223. DOI: 10.1016/s2666-6367(22)00441-9.
58 Prevalence of and Risk Factors for Cardiac, Pulmonary, and Neurologic Dysfunction Following Hematopoietic Cell Transplant for Sickle Cell Disease: A STAR StudyStenger E, Chellapandian D, Shah R, Gillepsie S, Xiang Y, Bhatia M, Chaudhury S, Eckrich M, Guilcher G, Jaroscak J, Kasow K, Krajewski J, Ngwube A, Olson T, Rangarajan H, Horan J, Krishnamurti L, Shenoy S, Abraham A. 58 Prevalence of and Risk Factors for Cardiac, Pulmonary, and Neurologic Dysfunction Following Hematopoietic Cell Transplant for Sickle Cell Disease: A STAR Study. Transplantation And Cellular Therapy 2022, 28: s49-s51. DOI: 10.1016/s2666-6367(22)00219-6.
21 Sickle Cell Disease Is a Risk Factor for Transplant Associated Thrombotic Microangiopathy in Children Undergoing Hematopoietic Cellular TherapySchoettler M, Spencer K, Lutterman D, Rumbika S, Haight A, Stenger E, Parikh S, Qayed M, Watkins B, Krishnamurti L, Williams K, Chonat S. 21 Sickle Cell Disease Is a Risk Factor for Transplant Associated Thrombotic Microangiopathy in Children Undergoing Hematopoietic Cellular Therapy. Transplantation And Cellular Therapy 2022, 28: s20-s21. DOI: 10.1016/s2666-6367(22)00182-8.
17 Polyclonality Strongly Correlates with Biologic Outcomes and Is Significantly Increased Following Improvements to the Phase 1/2 HGB-206 Protocol and Manufacturing of Lentiglobin for Sickle Cell Disease (SCD; bb1111) Gene Therapy (GT)Walters M, Thompson A, Mapara M, Kwiatkowski J, Krishnamurti L, Aygun B, Kasow K, Rifkin-Zenenberg S, Schmidt M, Pierciey F, Whitney D, Rogers C, Nnamani M, Foos M, Miller A, Zhang X, Lynch J, Kanter J, Tisdale J, Bonner M. 17 Polyclonality Strongly Correlates with Biologic Outcomes and Is Significantly Increased Following Improvements to the Phase 1/2 HGB-206 Protocol and Manufacturing of Lentiglobin for Sickle Cell Disease (SCD; bb1111) Gene Therapy (GT). Transplantation And Cellular Therapy 2022, 28: s16-s17. DOI: 10.1016/s2666-6367(22)00178-6.
Ramatroban for chemoprophylaxis and treatment of COVID-19: David takes on GoliathChiang K, Rizk J, Nelson D, Krishnamurti L, Subbian S, Imig J, Khan I, Reddy S, Gupta A. Ramatroban for chemoprophylaxis and treatment of COVID-19: David takes on Goliath. Expert Opinion On Therapeutic Targets 2022, 26: 13-28. PMID: 35068281, PMCID: PMC10119876, DOI: 10.1080/14728222.2022.2031975.
Effects of Music Therapy on Quality of Life in Adults with Sickle Cell Disease (MUSIQOLS): A Mixed Methods Feasibility StudyRodgers-Melnick S, Lin L, Gam K, de Santana Carvalho E, Jenerette C, Rowland D, Little J, Dusek J, Bakshi N, Krishnamurti L. Effects of Music Therapy on Quality of Life in Adults with Sickle Cell Disease (MUSIQOLS): A Mixed Methods Feasibility Study. Journal Of Pain Research 2022, 15: 71-91. PMID: 35046718, PMCID: PMC8760983, DOI: 10.2147/jpr.s337390.
Hematopoietic cell transplantation for sickle cell disease: updates and future directionsKrishnamurti L. Hematopoietic cell transplantation for sickle cell disease: updates and future directions. Hematology 2021, 2021: 181-189. PMID: 34889368, PMCID: PMC8791142, DOI: 10.1182/hematology.2021000251.
Long-Term Quality of Life after Hematopoietic Cell Transplantation for Sickle Cell Disease: A Preliminary Report from the Sickle Cell Transplant Evaluation of Long Term and Late Effects Registry (STELLAR)Arnold S, Bakshi N, Chang Z, Ross D, Abraham A, Bhatia M, Guilcher G, Haight A, Hsieh M, Kasow K, Lane P, Meacham L, Olowoselu F, Krishnamurti L. Long-Term Quality of Life after Hematopoietic Cell Transplantation for Sickle Cell Disease: A Preliminary Report from the Sickle Cell Transplant Evaluation of Long Term and Late Effects Registry (STELLAR). Blood 2021, 138: 425. DOI: 10.1182/blood-2021-154280.
Mobility and Muscle Strength in Recipients of Hematopoietic Cell Transplantation for Sickle Cell Disease: A Preliminary Report from Sickle Transplant Evaluation of Longterm and Late Effects Registry (STELLaR)Veludhandi A, John T, Bakshi N, Arnold S, Bhatia M, Lane P, Meacham L, Khemani K, Chaudhury S, Olowoselu F, Kasow K, Hsieh M, Abraham A, Guilcher G, Krishnamurti L. Mobility and Muscle Strength in Recipients of Hematopoietic Cell Transplantation for Sickle Cell Disease: A Preliminary Report from Sickle Transplant Evaluation of Longterm and Late Effects Registry (STELLaR). Blood 2021, 138: 3030. DOI: 10.1182/blood-2021-152383.
Preliminary Safety and Efficacy Results from Precizn-1: An Ongoing Phase 1/2 Study on Zinc Finger Nuclease-Modified Autologous CD34+ HSPCs for Sickle Cell Disease (SCD)Alavi A, Krishnamurti L, Abedi M, Galeon I, Reiner D, Smith S, Wang L, Ramezi A, Rendo P, Walters M. Preliminary Safety and Efficacy Results from Precizn-1: An Ongoing Phase 1/2 Study on Zinc Finger Nuclease-Modified Autologous CD34+ HSPCs for Sickle Cell Disease (SCD). Blood 2021, 138: 2930. DOI: 10.1182/blood-2021-151650.
Polyclonality Strongly Correlates with Biological Outcomes and Is Significantly Increased Following Improvements to the Phase 1/2 HGB-206 Protocol and Manufacturing of LentiGlobin for Sickle Cell Disease (SCD; bb1111) Gene Therapy (GT)Tisdale J, Thompson A, Mapara M, Kwiatkowski J, Krishnamurti L, Aygun B, Kasow K, Rifkin-Zenenberg S, Schmidt M, Pierciey F, Whitney D, Rogers C, Nnamani M, Foos M, Miller A, Zhang X, Lynch J, Walters M, Kanter J, Bonner M. Polyclonality Strongly Correlates with Biological Outcomes and Is Significantly Increased Following Improvements to the Phase 1/2 HGB-206 Protocol and Manufacturing of LentiGlobin for Sickle Cell Disease (SCD; bb1111) Gene Therapy (GT). Blood 2021, 138: 561. DOI: 10.1182/blood-2021-147760.
Sustained Improvements in Patient-Reported Quality of Life up to 24 Months Post-Treatment with LentiGlobin for Sickle Cell Disease (bb1111) Gene TherapyWalters M, Tisdale J, Mapara M, Krishnamurti L, Kwiatkowski J, Aygun B, Kasow K, Rifkin-Zenenberg S, Jaroscak J, Garbinsky D, Chirila C, Gallagher M, Zhang X, Ho P, Thompson A, Kanter J. Sustained Improvements in Patient-Reported Quality of Life up to 24 Months Post-Treatment with LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy. Blood 2021, 138: 7. DOI: 10.1182/blood-2021-146905.
A Decision Support Tool for Allogeneic Hematopoietic Stem Cell Transplantation for Children With Sickle Cell Disease: Acceptability and Usability StudyVeludhandi A, Ross D, Sinha C, McCracken C, Bakshi N, Krishnamurti L. A Decision Support Tool for Allogeneic Hematopoietic Stem Cell Transplantation for Children With Sickle Cell Disease: Acceptability and Usability Study. JMIR Formative Research 2021, 5: e30093. PMID: 34709190, PMCID: PMC8587189, DOI: 10.2196/30093.
Assessing Patient Preferences for Treatment Options for Pediatric Sickle Cell Disease: A Critical Review of Quantitative and Qualitative StudiesKatoch D, Krishnamurti L. Assessing Patient Preferences for Treatment Options for Pediatric Sickle Cell Disease: A Critical Review of Quantitative and Qualitative Studies. Patient Preference And Adherence 2021, 15: 2221-2229. PMID: 34629865, PMCID: PMC8493010, DOI: 10.2147/ppa.s264918.
Intraindividual pain variability and phenotypes of pain in sickle cell disease: a secondary analysis from the Pain in Sickle Cell Epidemiology StudyBakshi N, Gillespie S, McClish D, McCracken C, Smith W, Krishnamurti L. Intraindividual pain variability and phenotypes of pain in sickle cell disease: a secondary analysis from the Pain in Sickle Cell Epidemiology Study. Pain 2021, 163: 1102-1113. PMID: 34538841, PMCID: PMC9100443, DOI: 10.1097/j.pain.0000000000002479.
Hematopoietic Cell Transplantation Outcomes among Medicaid and Privately Insured Patients with Sickle Cell DiseaseMupfudze T, Meyer C, Preussler J, Mau L, Bolon Y, Steinert P, Arnold S, Saber W, Krishnamurti L. Hematopoietic Cell Transplantation Outcomes among Medicaid and Privately Insured Patients with Sickle Cell Disease. Transplantation And Cellular Therapy 2021, 27: 685.e1-685.e8. PMID: 33895405, PMCID: PMC8680220, DOI: 10.1016/j.jtct.2021.04.009.
A pilot study of the acceptability, feasibility and safety of yoga for chronic pain in sickle cell diseaseBakshi N, Cooley A, Ross D, Hawkins L, Sullivan M, Astles R, Sinha C, Katoch D, Peddineni M, Gee B, Lane P, Krishnamurti L. A pilot study of the acceptability, feasibility and safety of yoga for chronic pain in sickle cell disease. Complementary Therapies In Medicine 2021, 59: 102722. PMID: 33892094, PMCID: PMC8284565, DOI: 10.1016/j.ctim.2021.102722.
Gaps in Medicaid Coverage and Financial Toxicity: A Health Disparity in Hematopoietic Cell Transplantation for Sickle Cell DiseaseKrishnamurti L. Gaps in Medicaid Coverage and Financial Toxicity: A Health Disparity in Hematopoietic Cell Transplantation for Sickle Cell Disease. Transplantation And Cellular Therapy 2021, 27: 284-285. PMID: 33836866, DOI: 10.1016/j.jtct.2021.03.016.
386 Cryptogenic Organizing Pneumonia Following HLA Identical Hematopoietic Stem Cell Transplantation for Sickle Cell Disease: A Case Series of Three Pediatric PatientsBauchat A, Williams K, Simon D, Parikh S, Krishnamurti L. 386 Cryptogenic Organizing Pneumonia Following HLA Identical Hematopoietic Stem Cell Transplantation for Sickle Cell Disease: A Case Series of Three Pediatric Patients. Transplantation And Cellular Therapy 2021, 27: s321-s322. DOI: 10.1016/s2666-6367(21)00412-7.
13 Resolution of Serious Vaso-Occlusive Pain Crises: Results from the Ongoing Phase 1/2 HGB-206 Group C Study of LentiGlobin for Sickle Cell Disease (SCD; bb1111) Gene TherapyWalters M, Thompson A, Mapara M, Kwiatkowski J, Krishnamurti L, Aygun B, Kasow K, Rifkin-Zenenberg S, Schmidt M, DelCarpini J, Pierciey F, Miller A, Chen R, Goyal S, Kanter J, Tisdale J. 13 Resolution of Serious Vaso-Occlusive Pain Crises: Results from the Ongoing Phase 1/2 HGB-206 Group C Study of LentiGlobin for Sickle Cell Disease (SCD; bb1111) Gene Therapy. Transplantation And Cellular Therapy 2021, 27: s12-s13. DOI: 10.1016/s2666-6367(21)00039-7.
363 Hematopoietic Cell Transplant Outcomes Among Medicaid and Privately Insured Patients with Sickle Cell DiseaseMupfudze T, Meyer C, Krishnamurti L, Preussler J, Mau L, Bolon Y, Steinert P, Arnold S, Saber W. 363 Hematopoietic Cell Transplant Outcomes Among Medicaid and Privately Insured Patients with Sickle Cell Disease. Transplantation And Cellular Therapy 2021, 27: s306. DOI: 10.1016/s2666-6367(21)00389-4.
Hematopoietic Cell Transplantation for Sickle Cell DiseaseKrishnamurti L. Hematopoietic Cell Transplantation for Sickle Cell Disease. Frontiers In Pediatrics 2021, 8: 551170. PMID: 33469520, PMCID: PMC7813811, DOI: 10.3389/fped.2020.551170.
Mortality in sickle cell disease: A population‐based study in an aboriginal community in the Gudalur Valley, Nilgiris, Tamil Nadu, IndiaSheshadri V, Shabeer P, Santhirapala V, Jayaram A, Krishnamurti L, Menon N. Mortality in sickle cell disease: A population‐based study in an aboriginal community in the Gudalur Valley, Nilgiris, Tamil Nadu, India. Pediatric Blood & Cancer 2020, 68: e28875. PMID: 33381914, DOI: 10.1002/pbc.28875.
Educational needs of patients and caregivers living with sickle cell disease results in development of web‐based patient decision aidRoss D, Sinha C, Bakshi N, Krishnamurti L. Educational needs of patients and caregivers living with sickle cell disease results in development of web‐based patient decision aid. Journal Of Advanced Nursing 2020, 77: 1432-1441. PMID: 33277763, DOI: 10.1111/jan.14704.
Resolution of Serious Vaso-Occlusive Pain Crises and Reduction in Patient-Reported Pain Intensity: Results from the Ongoing Phase 1/2 HGB-206 Group C Study of LentiGlobin for Sickle Cell Disease (bb1111) Gene TherapyThompson A, Walters M, Mapara M, Kwiatkowski J, Krishnamurti L, Aygun B, Kasow K, Rifkin-Zenenberg S, Schmidt M, DelCarpini J, Pierciey F, Miller A, Gallagher M, Chen R, Goyal S, Kanter J, Tisdale J. Resolution of Serious Vaso-Occlusive Pain Crises and Reduction in Patient-Reported Pain Intensity: Results from the Ongoing Phase 1/2 HGB-206 Group C Study of LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy. Blood 2020, 136: 16-17. DOI: 10.1182/blood-2020-134940.
Risk Factors and Cardiovascular Disease (CVD) Related Outcomes in Hospitalized Patients with Hemophilia 10 Year Follow upDay J, Gupta A, Abro C, Jung K, Krishnamurti L, Takemoto C, Goel R. Risk Factors and Cardiovascular Disease (CVD) Related Outcomes in Hospitalized Patients with Hemophilia 10 Year Follow up. Blood 2020, 136: 30-31. DOI: 10.1182/blood-2020-136486.
Improvements in Health-Related Quality of Life for Patients Treated with LentiGlobin for Sickle Cell Disease (bb1111) Gene TherapyKanter J, Tisdale J, Mapara M, Kwiatkowski J, Krishnamurti L, Chen R, Gallagher M, Ding Y, Goyal S, Paramore C, Thompson A, Walters M. Improvements in Health-Related Quality of Life for Patients Treated with LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy. Blood 2020, 136: 10. DOI: 10.1182/blood-2020-136193.
Primary caregiver decision‐making in hematopoietic cell transplantation and gene therapy for sickle cell diseaseSinha C, Bakshi N, Ross D, Loewenstein G, Krishnamurti L. Primary caregiver decision‐making in hematopoietic cell transplantation and gene therapy for sickle cell disease. Pediatric Blood & Cancer 2020, 68: e28749-e28749. PMID: 33034129, PMCID: PMC8246626, DOI: 10.1002/pbc.28749.
Safety and feasibility of hematopoietic progenitor stem cell collection by mobilization with plerixafor followed by apheresis vs bone marrow harvest in patients with sickle cell disease in the multi‐center HGB‐206 trialTisdale J, Pierciey F, Bonner M, Thompson A, Krishnamurti L, Mapara M, Kwiatkowski J, Shestopalov I, Ribeil J, Huang W, Asmal M, Kanter J, Walters M. Safety and feasibility of hematopoietic progenitor stem cell collection by mobilization with plerixafor followed by apheresis vs bone marrow harvest in patients with sickle cell disease in the multi‐center HGB‐206 trial. American Journal Of Hematology 2020, 95: e239-e242. PMID: 32401372, DOI: 10.1002/ajh.25867.
Assessment of Patient and Caregiver Attitudes and Approaches to Decision-Making Regarding Bone Marrow Transplant for Sickle Cell DiseaseBakshi N, Katoch D, Sinha C, Ross D, Quarmyne M, Loewenstein G, Krishnamurti L. Assessment of Patient and Caregiver Attitudes and Approaches to Decision-Making Regarding Bone Marrow Transplant for Sickle Cell Disease. JAMA Network Open 2020, 3: e206742. PMID: 32469414, PMCID: PMC7260617, DOI: 10.1001/jamanetworkopen.2020.6742.
Patient and family experience with chronic transfusion therapy for sickle cell disease: A qualitative studyHawkins L, Sinha C, Ross D, Yee M, Quarmyne M, Krishnamurti L, Bakshi N. Patient and family experience with chronic transfusion therapy for sickle cell disease: A qualitative study. BMC Pediatrics 2020, 20: 172. PMID: 32305060, PMCID: PMC7165370, DOI: 10.1186/s12887-020-02078-w.
Should young children with sickle cell disease and an available human leukocyte antigen identical sibling donor be offered hematopoietic cell transplantation?Krishnamurti L. Should young children with sickle cell disease and an available human leukocyte antigen identical sibling donor be offered hematopoietic cell transplantation? Hematology/Oncology And Stem Cell Therapy 2020, 13: 53-57. PMID: 32202246, DOI: 10.1016/j.hemonc.2019.12.008.
Lentiglobin for Sickle Cell Disease (SCD) Gene Therapy (GT): Updated Results in Group C Patients from the Phase 1/2 Hgb-206 StudyWalters M, Kanter J, Kwiatkowski J, Krishnamurti L, Mapara M, Schmidt M, Miller A, Pierciey F, Bonner M, Huang W, Ribeil J, Thompson A, Tisdale J. Lentiglobin for Sickle Cell Disease (SCD) Gene Therapy (GT): Updated Results in Group C Patients from the Phase 1/2 Hgb-206 Study. Transplantation And Cellular Therapy 2020, 26: s1-s2. DOI: 10.1016/j.bbmt.2019.12.136.
What Prompts Parents of Children with Sickle Cell Disease to Consider a Curative Option in This Era of Novel Hematopoietic Cell Donor Sources and Gene Modification?Sinha C, Bakshi N, Ross D, Krishnamurti L. What Prompts Parents of Children with Sickle Cell Disease to Consider a Curative Option in This Era of Novel Hematopoietic Cell Donor Sources and Gene Modification? Transplantation And Cellular Therapy 2020, 26: s202. DOI: 10.1016/j.bbmt.2019.12.694.
Safety of Autologous Hematopoietic Stem Cell Transplantation with Gene Addition Therapy for Transfusion-Dependent β-Thalassemia, Sickle Cell Disease, and Cerebral AdrenoleukodystrophyWalters M, Locatelli F, Thrasher A, Tisdale J, Orchard P, Duncan C, Kühl J, De Oliveira S, Sauer M, Kulozik A, Yannaki E, Hongeng S, Mapara M, Krishnamurti L, Hermine O, Blanche S, Aubourg P, Smith N, Shi W, Colvin R, McNeil E, Ribeil J, Cavazzana M, Williams D. Safety of Autologous Hematopoietic Stem Cell Transplantation with Gene Addition Therapy for Transfusion-Dependent β-Thalassemia, Sickle Cell Disease, and Cerebral Adrenoleukodystrophy. Transplantation And Cellular Therapy 2020, 26: s38-s39. DOI: 10.1016/j.bbmt.2019.12.104.
Prevalence and predictors of chronic pain intensity and disability among adults with sickle cell diseaseMatthie N, Jenerette C, Gibson A, Paul S, Higgins M, Krishnamurti L. Prevalence and predictors of chronic pain intensity and disability among adults with sickle cell disease. Health Psychology Open 2020, 7: 2055102920917250. PMID: 32426150, PMCID: PMC7218472, DOI: 10.1177/2055102920917250.
How I treat sickle cell disease with hematopoietic cell transplantationStenger E, Shenoy S, Krishnamurti L. How I treat sickle cell disease with hematopoietic cell transplantation. Blood 2019, 134: 2249-2260. PMID: 31697818, PMCID: PMC6923666, DOI: 10.1182/blood.2019000821.
End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settingsFarrell A, Panepinto J, Desai A, Kassim A, Lebensburger J, Walters M, Bauer D, Blaylark R, DiMichele D, Gladwin M, Green N, Hassell K, Kato G, Klings E, Kohn D, Krishnamurti L, Little J, Makani J, Malik P, McGann P, Minniti C, Morris C, Odame I, Oneal P, Setse R, Sharma P, Shenoy S. End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings. Blood Advances 2019, 3: 4002-4020. PMID: 31809537, PMCID: PMC6963248, DOI: 10.1182/bloodadvances.2019000883.
Comparative Effectiveness of a Web-Based Patient Decision Aid for Therapeutic Options for Sickle Cell Disease: Randomized Controlled TrialKrishnamurti L, Ross D, Sinha C, Leong T, Bakshi N, Mittal N, Veludhandi D, Pham A, Taneja A, Gupta K, Nwanze J, Matthews A, Joshi S, Olivieri V, Arjunan S, Okonkwo I, Lukombo I, Lane P, Bakshi N, Loewenstein G. Comparative Effectiveness of a Web-Based Patient Decision Aid for Therapeutic Options for Sickle Cell Disease: Randomized Controlled Trial. Journal Of Medical Internet Research 2019, 21: e14462. PMID: 31799940, PMCID: PMC6934048, DOI: 10.2196/14462.
Resolution of Sickle Cell Disease Manifestations in Patients Treated with Lentiglobin Gene Therapy: Updated Results from the Phase 1/2 Hgb-206 Group C StudyKanter J, Tisdale J, Mapara M, Kwiatkowski J, Krishnamurti L, Schmidt M, Miller A, Pierciey F, Huang W, Ribeil J, Thompson A, Walters M. Resolution of Sickle Cell Disease Manifestations in Patients Treated with Lentiglobin Gene Therapy: Updated Results from the Phase 1/2 Hgb-206 Group C Study. Blood 2019, 134: 990. DOI: 10.1182/blood-2019-128894.
Excellent Overall Survival and Low Incidence of Late Effects in Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Sickle Cell Disease: A Report from the Center for International Blood and Marrow Transplant Research (CIBMTR)Stenger E, Phelan R, Shaw B, Battiwalla M, Bo-Subait S, Brazauskas R, Buchbinder D, Hamilton B, Shenoy S, Krishnamurti L. Excellent Overall Survival and Low Incidence of Late Effects in Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Sickle Cell Disease: A Report from the Center for International Blood and Marrow Transplant Research (CIBMTR). Blood 2019, 134: 697. DOI: 10.1182/blood-2019-128797.
Transcranial Doppler Screening in Children with Sickle Cell Anemia Is Feasible in Central India and Reveals High Risk of StrokeJain D, Ganesan K, Sahota S, Darbari D, Krishnamurti L, Kirkham F. Transcranial Doppler Screening in Children with Sickle Cell Anemia Is Feasible in Central India and Reveals High Risk of Stroke. Blood 2019, 134: 2279. DOI: 10.1182/blood-2019-131416.
Exploring the Drivers of Potential Clinical Benefit in Initial Patients Treated in the Hgb-206 Study of Lentiglobin for Sickle Cell Disease (SCD) Gene TherapyWalters M, Tisdale J, Kwiatkowski J, Krishnamurti L, Mapara M, Schmidt M, Miller A, Pierciey F, Huang W, Ribeil J, Kanter J, Thompson A. Exploring the Drivers of Potential Clinical Benefit in Initial Patients Treated in the Hgb-206 Study of Lentiglobin for Sickle Cell Disease (SCD) Gene Therapy. Blood 2019, 134: 2061. DOI: 10.1182/blood-2019-128814.
A Phase II Trial to Compare Allogeneic Transplant Vs. Standard of Care for Severe Sickle Cell Disease: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 1503Eapen M, Neuberg D, Mendizabal A, Stevenson K, Antin J, DiFronzo N, Rassi F, Lulla P, Waller E, Garrison J, Smith S, Sullivan K, Walters M, Krishnamurti L. A Phase II Trial to Compare Allogeneic Transplant Vs. Standard of Care for Severe Sickle Cell Disease: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 1503. Blood 2019, 134: 4592. DOI: 10.1182/blood-2019-126793.
Preliminary Results of a Phase 1/2 Clinical Study of Zinc Finger Nuclease-Mediated Editing of BCL11A in Autologous Hematopoietic Stem Cells for Transfusion-Dependent Beta ThalassemiaSmith A, Schiller G, Vercellotti G, Kwiatkowski J, Krishnamurti L, Esrick E, Williams D, Miller W, Woolfson A, Walters M. Preliminary Results of a Phase 1/2 Clinical Study of Zinc Finger Nuclease-Mediated Editing of BCL11A in Autologous Hematopoietic Stem Cells for Transfusion-Dependent Beta Thalassemia. Blood 2019, 134: 3544. DOI: 10.1182/blood-2019-125743.
Associated Co-Morbidities, Healthcare Utilization, and Mortality in Hospitalized Children and Adults with Hemophilia in the United States: Updated Nationally Representative Estimates and a Comparative AnalysisGupta A, Hannan A, Maini R, Bitner S, Stone S, Regmi M, Tobian A, Josephson C, Krishnamurti L, Takemoto C, Goel R. Associated Co-Morbidities, Healthcare Utilization, and Mortality in Hospitalized Children and Adults with Hemophilia in the United States: Updated Nationally Representative Estimates and a Comparative Analysis. Blood 2019, 134: 4711. DOI: 10.1182/blood-2019-123161.
S1633 UPDATED RESULTS FROM THE HGB‐206 STUDY IN PATIENTS WITH SEVERE SICKLE CELL DISEASE TREATED UNDER A REVISED PROTOCOL WITH LENTIGLOBIN GENE THERAPY USING PLERIXAFOR‐MOBILISED HAEMATOPOIETIC STEM CELLSKanter J, Thompson A, Mapara M, Kwiatkowski J, Krishnamurti L, Schmidt M, Miller A, Pierciey F, Huang W, Ribeil J, Walters M, Tisdale J. S1633 UPDATED RESULTS FROM THE HGB‐206 STUDY IN PATIENTS WITH SEVERE SICKLE CELL DISEASE TREATED UNDER A REVISED PROTOCOL WITH LENTIGLOBIN GENE THERAPY USING PLERIXAFOR‐MOBILISED HAEMATOPOIETIC STEM CELLS. HemaSphere 2019, 3: 754-755. DOI: 10.1097/01.hs9.0000564780.30358.eb.
Curative Therapies for Sickle Cell Disease.Khemani K, Katoch D, Krishnamurti L. Curative Therapies for Sickle Cell Disease. Ochsner Journal 2019, 19: 131-137. PMID: 31258425, PMCID: PMC6584191, DOI: 10.31486/toj.18.0044.
Management of Chronic Pain in Adults Living With Sickle Cell Disease in the Era of the Opioid EpidemicSinha C, Bakshi N, Ross D, Krishnamurti L. Management of Chronic Pain in Adults Living With Sickle Cell Disease in the Era of the Opioid Epidemic. JAMA Network Open 2019, 2: e194410. PMID: 31125105, PMCID: PMC6632133, DOI: 10.1001/jamanetworkopen.2019.4410.
Lentiglobin Gene Therapy in Patients with Sickle Cell Disease: Updated Interim Results from Hgb-206Mapara M, Tisdale J, Kanter J, Kwiatkowski J, Krishnamurti L, Schmidt M, Miller A, Pierciey F, Shi W, Ribeil J, Asmal M, Thompson A, Walters M. Lentiglobin Gene Therapy in Patients with Sickle Cell Disease: Updated Interim Results from Hgb-206. Transplantation And Cellular Therapy 2019, 25: s64-s65. DOI: 10.1016/j.bbmt.2018.12.147.
Administration of BPX-501 Cells Following Αβ T and B-Cell-Depleted HLA Haploidentical HSCT (haplo-HSCT) in Children with Acute Leukemias (AL)Galaverna F, Ruggeri A, Merli P, Kapoor N, Agarwal-Hashmi R, Aquino V, Jacobsohn D, Qasim W, Nemecek E, Krishnamurti L, Manwani D, Kuhn M, Locatelli F, Naik S. Administration of BPX-501 Cells Following Αβ T and B-Cell-Depleted HLA Haploidentical HSCT (haplo-HSCT) in Children with Acute Leukemias (AL). Transplantation And Cellular Therapy 2019, 25: s15-s16. DOI: 10.1016/j.bbmt.2018.12.082.
Application of Parafilm As a Physical Barrier on CVC Connections Is Feasible and May Reduce Clabsi Among Pediatric HCT PatientsStenger E, Newton J, Leong T, Kendrick L, McManus L, Rooke C, Krishnamurti L. Application of Parafilm As a Physical Barrier on CVC Connections Is Feasible and May Reduce Clabsi Among Pediatric HCT Patients. Transplantation And Cellular Therapy 2019, 25: s131. DOI: 10.1016/j.bbmt.2018.12.416.
Bone marrow transplantation for adolescents and young adults with sickle cell disease: Results of a prospective multicenter pilot studyKrishnamurti L, Neuberg D, Sullivan K, Kamani N, Abraham A, Campigotto F, Zhang W, Dahdoul T, De Castro L, Parikh S, Bakshi N, Haight A, Hassell K, Loving R, Rosenthal J, Smith S, Smith W, Spearman M, Stevenson K, Wu C, Wiedl C, Waller E, Walters M. Bone marrow transplantation for adolescents and young adults with sickle cell disease: Results of a prospective multicenter pilot study. American Journal Of Hematology 2019, 94: 446-454. PMID: 30637784, PMCID: PMC6542639, DOI: 10.1002/ajh.25401.
Platelet transfusion practices in immune thrombocytopenia related hospitalizationsGoel R, Chopra S, Tobian A, Ness P, Frank S, Cushing M, Vasovic L, Kaicker S, Takemoto C, Josephson C, Nellis M, Bussel J, Krishnamurti L. Platelet transfusion practices in immune thrombocytopenia related hospitalizations. Transfusion 2018, 59: 169-176. PMID: 30520045, DOI: 10.1111/trf.15069.
Administration of Rimiducid Following Haploidentical BPX-501 Cells in Children with Malignant or Non-Malignant Disorders Who Develop Graft-Versus-Host-Disease (GvHD)Elkeky R, Jacobsohn D, Agarwal R, Naik S, Kapoor N, Krishnamurti L, Slatter M, Galaverna F, Merli P, Aldinger M, Locatelli F. Administration of Rimiducid Following Haploidentical BPX-501 Cells in Children with Malignant or Non-Malignant Disorders Who Develop Graft-Versus-Host-Disease (GvHD). Blood 2018, 132: 2207. DOI: 10.1182/blood-2018-99-119792.
Administration of BPX-501 Cells Following Aβ T and B-Cell-Depleted HLA Haploidentical HSCT (haplo-HSCT) in Children with Acute LeukemiasLocatelli F, Ruggeri A, Merli P, Naik S, Agarwal R, Aquino V, Jacobsohn D, Qasim W, Nemecek E, Krishnamurti L, Manwani D, Kuhn M, Kapoor N. Administration of BPX-501 Cells Following Aβ T and B-Cell-Depleted HLA Haploidentical HSCT (haplo-HSCT) in Children with Acute Leukemias. Blood 2018, 132: 307. DOI: 10.1182/blood-2018-99-119481.
Vaccination Adherence in Pediatric Patients Post-Hematopoietic Stem Cell TransplantKhemani K, Steele M, Bakshi N, Krishnamurti L, Yildirim I. Vaccination Adherence in Pediatric Patients Post-Hematopoietic Stem Cell Transplant. Blood 2018, 132: 3406. DOI: 10.1182/blood-2018-99-119283.
Current Results of Lentiglobin Gene Therapy in Patients with Severe Sickle Cell Disease Treated Under a Refined Protocol in the Phase 1 Hgb-206 StudyTisdale J, Kanter J, Mapara M, Kwiatkowski J, Krishnamurti L, Schmidt M, Miller A, Pierciey F, Shi W, Ribeil J, Asmal M, Thompson A, Walters M. Current Results of Lentiglobin Gene Therapy in Patients with Severe Sickle Cell Disease Treated Under a Refined Protocol in the Phase 1 Hgb-206 Study. Blood 2018, 132: 1026. DOI: 10.1182/blood-2018-99-113480.
Outcomes for Initial Patient Cohorts with up to 33 Months of Follow-up in the Hgb-206 Phase 1 TrialKanter J, Tisdale J, Kwiatkowski J, Krishnamurti L, Mapara M, Schmidt M, Miller A, Pierciey F, Shi W, Ribeil J, Walters M, Thompson A. Outcomes for Initial Patient Cohorts with up to 33 Months of Follow-up in the Hgb-206 Phase 1 Trial. Blood 2018, 132: 1080. DOI: 10.1182/blood-2018-99-113477.
A Qualitative Study of Chronic Pain and Self-Management in Adults with Sickle Cell DiseaseMatthie N, Ross D, Sinha C, Khemani K, Bakshi N, Krishnamurti L. A Qualitative Study of Chronic Pain and Self-Management in Adults with Sickle Cell Disease. Journal Of The National Medical Association 2018, 111: 158-168. PMID: 30266214, PMCID: PMC6433553, DOI: 10.1016/j.jnma.2018.08.001.
Ovarian Sertoli–Leydig tumor after bone marrow transplant for sickle cell diseasePhillips L, Krishnamurti L, Rytting H, Olson T. Ovarian Sertoli–Leydig tumor after bone marrow transplant for sickle cell disease. Pediatric Blood & Cancer 2018, 65: e27367. PMID: 30039911, DOI: 10.1002/pbc.27367.
From trust to skepticism: An in-depth analysis across age groups of adults with sickle cell disease on their perspectives regarding hydroxyureaSinha C, Bakshi N, Ross D, Krishnamurti L. From trust to skepticism: An in-depth analysis across age groups of adults with sickle cell disease on their perspectives regarding hydroxyurea. PLOS ONE 2018, 13: e0199375. PMID: 29949647, PMCID: PMC6021071, DOI: 10.1371/journal.pone.0199375.
Pain catastrophizing is associated with poorer health-related quality of life in pediatric patients with sickle cell diseaseBakshi N, Lukombo I, Belfer I, Krishnamurti L. Pain catastrophizing is associated with poorer health-related quality of life in pediatric patients with sickle cell disease. Journal Of Pain Research 2018, 11: 947-953. PMID: 29773954, PMCID: PMC5947835, DOI: 10.2147/jpr.s151198.
Sickle cell diseaseKato G, Piel F, Reid C, Gaston M, Ohene-Frempong K, Krishnamurti L, Smith W, Panepinto J, Weatherall D, Costa F, Vichinsky E. Sickle cell disease. Nature Reviews Disease Primers 2018, 4: 18010. PMID: 29542687, DOI: 10.1038/nrdp.2018.10.
Association of genetic variation in COMT gene with pain related to sickle cell disease in patients from the walk-PHaSST studyZhang Y, Belfer I, Nouraie M, Zeng Q, Goel R, Chu Y, Krasiy I, Krishnamurti L. Association of genetic variation in COMT gene with pain related to sickle cell disease in patients from the walk-PHaSST study. Journal Of Pain Research 2018, 11: 537-543. PMID: 29559808, PMCID: PMC5856032, DOI: 10.2147/jpr.s149958.
188 Single-Agent Plerixafor Mobilization to Collect Autologous Stem Cells for Use in Gene Therapy for Severe Sickle Cell DiseaseTisdale J, Kanter J, Hsieh M, Krishnamurti L, Kwiatkowski J, Kamble R, von Kalle C, Miller A, Pierciey F, Shi W, Asmal M, Thompson A, Walters M. 188 Single-Agent Plerixafor Mobilization to Collect Autologous Stem Cells for Use in Gene Therapy for Severe Sickle Cell Disease. Transplantation And Cellular Therapy 2018, 24: s174. DOI: 10.1016/j.bbmt.2017.12.108.
Quantitative sensory testing is feasible and is well-tolerated in patients with sickle cell disease following a vaso-occlusive episodeBakshi N, Lukombo I, Belfer I, Krishnamurti L. Quantitative sensory testing is feasible and is well-tolerated in patients with sickle cell disease following a vaso-occlusive episode. Journal Of Pain Research 2018, 11: 435-443. PMID: 29503580, PMCID: PMC5827673, DOI: 10.2147/jpr.s150066.
Presence of pain on three or more days of the week is associated with worse patient reported outcomes in adults with sickle cell diseaseBakshi N, Ross D, Krishnamurti L. Presence of pain on three or more days of the week is associated with worse patient reported outcomes in adults with sickle cell disease. Journal Of Pain Research 2018, 11: 313-318. PMID: 29445298, PMCID: PMC5810514, DOI: 10.2147/jpr.s150065.
Successful Plerixafor-Mediated Mobilization, Apheresis, and Lentiviral Vector Transduction of Hematopoietic Stem Cells in Patients with Severe Sickle Cell DiseaseTisdale J, Pierciey F, Kamble R, Kanter J, Krishnamurti L, Kwiatkowski J, Thompson A, Shestopalov I, Bonner M, Joseney-Antoine M, Asmal M, Walters M. Successful Plerixafor-Mediated Mobilization, Apheresis, and Lentiviral Vector Transduction of Hematopoietic Stem Cells in Patients with Severe Sickle Cell Disease. Blood 2017, 130: 990. DOI: 10.1182/blood.v130.suppl_1.990.990.
Acute Chest Syndrome in Children with Sickle Cell DiseaseJain S, Bakshi N, Krishnamurti L. Acute Chest Syndrome in Children with Sickle Cell Disease. Pediatric Allergy Immunology And Pulmonology 2017, 30: 191-201. PMID: 29279787, PMCID: PMC5733742, DOI: 10.1089/ped.2017.0814.
Experiences and Decision Making in Hematopoietic Stem Cell Transplant in Sickle Cell Disease: Patients' and Caregivers' PerspectivesKhemani K, Ross D, Sinha C, Haight A, Bakshi N, Krishnamurti L. Experiences and Decision Making in Hematopoietic Stem Cell Transplant in Sickle Cell Disease: Patients' and Caregivers' Perspectives. Transplantation And Cellular Therapy 2017, 24: 1041-1048. PMID: 29196076, DOI: 10.1016/j.bbmt.2017.11.018.
Proponent or collaborative: Physician perspectives and approaches to disease modifying therapies in sickle cell diseaseBakshi N, Sinha C, Ross D, Khemani K, Loewenstein G, Krishnamurti L. Proponent or collaborative: Physician perspectives and approaches to disease modifying therapies in sickle cell disease. PLOS ONE 2017, 12: e0178413. PMID: 28727801, PMCID: PMC5518995, DOI: 10.1371/journal.pone.0178413.
Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL™ Sickle Cell Disease ModulePanepinto J, Paul Scott J, Badaki-Makun O, Darbari D, Chumpitazi C, Airewele G, Ellison A, Smith-Whitley K, Mahajan P, Sarnaik S, Charles Casper T, Cook L, Leonard J, Hulbert M, Powell E, Liem R, Hickey R, Krishnamurti L, Hillery C, Brousseau D, for the Pediatric Emergency Care Applied Research Network (PECARN). Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL™ Sickle Cell Disease Module. Health And Quality Of Life Outcomes 2017, 15: 124. PMID: 28606098, PMCID: PMC5468970, DOI: 10.1186/s12955-017-0700-2.
Psychological Characteristics and Pain Frequency Are Associated With Experimental Pain Sensitivity in Pediatric Patients With Sickle Cell DiseaseBakshi N, Lukombo I, Shnol H, Belfer I, Krishnamurti L. Psychological Characteristics and Pain Frequency Are Associated With Experimental Pain Sensitivity in Pediatric Patients With Sickle Cell Disease. Journal Of Pain 2017, 18: 1216-1228. PMID: 28602692, DOI: 10.1016/j.jpain.2017.05.005.
Novel Metrics in the Longitudinal Evaluation of Pain Data in Sickle Cell DiseaseBakshi N, Smith M, Ross D, Krishnamurti L. Novel Metrics in the Longitudinal Evaluation of Pain Data in Sickle Cell Disease. The Clinical Journal Of Pain 2017, 33: 517-527. PMID: 27584817, DOI: 10.1097/ajp.0000000000000431.
91 Intact phenotype and functionality of bone marrow derived mesenchymal stromal cells from individuals with sickle cell diseaseStenger E, Chinnadurai R, Yuan S, Garcia M, Arafat D, Gibson G, Krishnamurti L, Galipeau J. 91 Intact phenotype and functionality of bone marrow derived mesenchymal stromal cells from individuals with sickle cell disease. Cytotherapy 2017, 19: s45. DOI: 10.1016/j.jcyt.2017.02.103.
Bone Marrow–Derived Mesenchymal Stromal Cells from Patients with Sickle Cell Disease Display Intact FunctionalityStenger E, Chinnadurai R, Yuan S, Garcia M, Arafat D, Gibson G, Krishnamurti L, Galipeau J. Bone Marrow–Derived Mesenchymal Stromal Cells from Patients with Sickle Cell Disease Display Intact Functionality. Transplantation And Cellular Therapy 2017, 23: 736-745. PMID: 28132869, PMCID: PMC5390328, DOI: 10.1016/j.bbmt.2017.01.081.
Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantationGluckman E, Cappelli B, Bernaudin F, Labopin M, Volt F, Carreras J, Pinto Simões B, Ferster A, Dupont S, de la Fuente J, Dalle J, Zecca M, Walters M, Krishnamurti L, Bhatia M, Leung K, Yanik G, Kurtzberg J, Dhedin N, Kuentz M, Michel G, Apperley J, Lutz P, Neven B, Bertrand Y, Vannier J, Ayas M, Cavazzana M, Matthes-Martin S, Rocha V, Elayoubi H, Kenzey C, Bader P, Locatelli F, Ruggeri A, Eapen M. Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. Blood 2016, 129: 1548-1556. PMID: 27965196, PMCID: PMC5356458, DOI: 10.1182/blood-2016-10-745711.
What Are the Expectations of Patients in Decision Making Process for Disease Modifying Therapies for Sickle Cell Disease: Do They Care about Shared Decision Making?Ross D, Bakshi N, Khemani K, Sinha C, Loewenstein G, Krishnamurti L. What Are the Expectations of Patients in Decision Making Process for Disease Modifying Therapies for Sickle Cell Disease: Do They Care about Shared Decision Making? Blood 2016, 128: 5968. DOI: 10.1182/blood.v128.22.5968.5968.
Development, Implementation, and Testing of a Web Based Decision Aid for Facilitating Shared Decision Making for Disease Modifying Therapies for Sickle Cell DiseaseKrishnamurti L, Ross D, Bakshi N, Khemani K, Sinha C, Loewenstein G. Development, Implementation, and Testing of a Web Based Decision Aid for Facilitating Shared Decision Making for Disease Modifying Therapies for Sickle Cell Disease. Blood 2016, 128: 5919. DOI: 10.1182/blood.v128.22.5919.5919.
Interim Results from a Phase 1/2 Clinical Study of Lentiglobin Gene Therapy for Severe Sickle Cell DiseaseKanter J, Walters M, Hsieh M, Krishnamurti L, Kwiatkowski J, Kamble R, von Kalle C, Kuypers F, Cavazzana M, Leboulch P, Joseney-Antoine M, Asmal M, Thompson A, Tisdale J. Interim Results from a Phase 1/2 Clinical Study of Lentiglobin Gene Therapy for Severe Sickle Cell Disease. Blood 2016, 128: 1176. DOI: 10.1182/blood.v128.22.1176.1176.
Shared Decision Making or Physician Advocate for a Particular Treatment Option: A Spectrum of Approaches to Decision Making about Disease Modifying Therapies in Sickle Cell DiseaseBakshi N, Sinha C, Ross D, Khemani K, Loewenstein G, Krishnamurti L. Shared Decision Making or Physician Advocate for a Particular Treatment Option: A Spectrum of Approaches to Decision Making about Disease Modifying Therapies in Sickle Cell Disease. Blood 2016, 128: 4757. DOI: 10.1182/blood.v128.22.4757.4757.
CMV Viremia and African-American Ethnicity Are Risk Factors for Post-Engraftment Blood Stream Infections in Pediatric Allogeneic Blood and Marrow TransplantationSano H, Hilinski J, Applegate K, Camacho-Gonzalez A, Chandrakasan S, Chiang K, Haight A, Krishnamurti L, Stenger E, Qayed M, Horan J. CMV Viremia and African-American Ethnicity Are Risk Factors for Post-Engraftment Blood Stream Infections in Pediatric Allogeneic Blood and Marrow Transplantation. Blood 2016, 128: 3397. DOI: 10.1182/blood.v128.22.3397.3397.
Experiences and Decision Making for Bone Marrow Transplant in Sickle Cell Disease: Patients and Caregivers PerspectiveKhemani K, Ross D, Haight A, Sinha C, Bakshi N, Krishnamurti L. Experiences and Decision Making for Bone Marrow Transplant in Sickle Cell Disease: Patients and Caregivers Perspective. Blood 2016, 128: 2393. DOI: 10.1182/blood.v128.22.2393.2393.
A trial of unrelated donor marrow transplantation for children with severe sickle cell diseaseShenoy S, Eapen M, Panepinto J, Logan B, Wu J, Abraham A, Brochstein J, Chaudhury S, Godder K, Haight A, Kasow K, Leung K, Andreansky M, Bhatia M, Dalal J, Haines H, Jaroscak J, Lazarus H, Levine J, Krishnamurti L, Margolis D, Megason G, Yu L, Pulsipher M, Gersten I, DiFronzo N, Horowitz M, Walters M, Kamani N. A trial of unrelated donor marrow transplantation for children with severe sickle cell disease. Blood 2016, 128: 2561-2567. PMID: 27625358, PMCID: PMC5123194, DOI: 10.1182/blood-2016-05-715870.
Iron-Deficiency AnemiaKrishnamurti L. Iron-Deficiency Anemia. 2016, 2217-2227. DOI: 10.1542/9781610020473-part07-ch279.
Clinical events in a large prospective cohort of children with sickle cell disease in Nagpur, India: evidence against a milder clinical phenotype in IndiaJain D, Arjunan A, Sarathi V, Jain H, Bhandarwar A, Vuga M, Krishnamurti L. Clinical events in a large prospective cohort of children with sickle cell disease in Nagpur, India: evidence against a milder clinical phenotype in India. Pediatric Blood & Cancer 2016, 63: 1814-1821. PMID: 27279568, DOI: 10.1002/pbc.26085.
Haematopoietic stem cell transplantation for sickle cell disease – current practice and new approachesArnold S, Bhatia M, Horan J, Krishnamurti L. Haematopoietic stem cell transplantation for sickle cell disease – current practice and new approaches. British Journal Of Haematology 2016, 174: 515-525. PMID: 27255787, DOI: 10.1111/bjh.14167.
Gonadal shielding technique to preserve fertility in male pediatric patients treated with total body irradiation for stem cell transplantationSayan M, Cassidy R, Butker E, Nanda R, Krishnamurti L, Khan M, Esiashvili N. Gonadal shielding technique to preserve fertility in male pediatric patients treated with total body irradiation for stem cell transplantation. Bone Marrow Transplantation 2016, 51: 997-998. PMID: 26950374, DOI: 10.1038/bmt.2016.25.
BPX-501 Cells (Donor T Cells Transduced with iC9 Suicide Gene) Treatment Following TCR Alpha Beta Depleted Stem Cell Transplantation in Adults and Children with Hematological DisordersVusirikala M, Naik S, Maziarz R, Baumeister S, Aquino V, Ma H, Moseley A, Woolfrey A, Krishnamurti L, Chen G, Sandmaier B, Bertaina A, Perales M, Williams D, Kapoor N. BPX-501 Cells (Donor T Cells Transduced with iC9 Suicide Gene) Treatment Following TCR Alpha Beta Depleted Stem Cell Transplantation in Adults and Children with Hematological Disorders. Transplantation And Cellular Therapy 2016, 22: s361. DOI: 10.1016/j.bbmt.2015.11.863.
Bone Marrow Derived Mesenchymal Stromal Cells from Patients with Sickle Cell Disease Display Normal Phenotype and Immunomodulatory CapacityStenger E, Chinnadurai R, Yuan S, Garcia M, Krishnamurti L, Copland I, Galipeau J. Bone Marrow Derived Mesenchymal Stromal Cells from Patients with Sickle Cell Disease Display Normal Phenotype and Immunomodulatory Capacity. Transplantation And Cellular Therapy 2016, 22: s148-s149. DOI: 10.1016/j.bbmt.2015.11.495.
Mesenchymal stromal cells to modulate immune reconstitution early post-hematopoietic cell transplantationStenger E, Krishnamurti L, Galipeau J. Mesenchymal stromal cells to modulate immune reconstitution early post-hematopoietic cell transplantation. BMC Immunology 2015, 16: 74. PMID: 26674007, PMCID: PMC4681052, DOI: 10.1186/s12865-015-0135-7.
Impact of Psychological Covariates on Experimental Pain Sensitivity in Children and Adolescents with SCDBakshi N, Lukombo I, Belfer I, Krishnamurti L. Impact of Psychological Covariates on Experimental Pain Sensitivity in Children and Adolescents with SCD. Blood 2015, 126: 985. DOI: 10.1182/blood.v126.23.985.985.
Results of a Multicenter Pilot Investigation of Bone Marrow Transplantation in Adults with Sickle Cell Disease (STRIDE)Krishnamurti L, Sullivan K, Kamani N, Waller E, Abraham A, Campigotto F, Zhang W, Smith S, Hassell K, Decastro L, Wu C, Neuberg D, Walters M. Results of a Multicenter Pilot Investigation of Bone Marrow Transplantation in Adults with Sickle Cell Disease (STRIDE). Blood 2015, 126: 543. DOI: 10.1182/blood.v126.23.543.543.
Initial Results from Study Hgb-206: A Phase 1 Study Evaluating Gene Therapy By Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with the Lentiglobin BB305 Lentiviral Vector in Subjects with Severe Sickle Cell DiseaseKanter J, Walters M, Hsieh M, Thompson A, Krishnamurti L, Kwiatkowski J, Kamble R, von Kalle C, Kuypers F, Cavazzana M, Leboulch P, Sandler L, Soni S, Tisdale J. Initial Results from Study Hgb-206: A Phase 1 Study Evaluating Gene Therapy By Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with the Lentiglobin BB305 Lentiviral Vector in Subjects with Severe Sickle Cell Disease. Blood 2015, 126: 3233. DOI: 10.1182/blood.v126.23.3233.3233.
Indications and Results of HLA-Identical Sibling Hematopoietic Cell Transplantation for Sickle Cell DiseaseWalters M, De Castro L, Sullivan K, Krishnamurti L, Kamani N, Bredeson C, Neuberg D, Hassell K, Farnia S, Campbell A, Petersdorf E. Indications and Results of HLA-Identical Sibling Hematopoietic Cell Transplantation for Sickle Cell Disease. Transplantation And Cellular Therapy 2015, 22: 207-211. PMID: 26500093, PMCID: PMC5031360, DOI: 10.1016/j.bbmt.2015.10.017.
Hydroxyurea therapy for children with sickle cell disease: describing how caregivers make this decisionCreary S, Zickmund S, Ross D, Krishnamurti L, Bogen D. Hydroxyurea therapy for children with sickle cell disease: describing how caregivers make this decision. BMC Research Notes 2015, 8: 372. PMID: 26303306, PMCID: PMC4548690, DOI: 10.1186/s13104-015-1344-0.
A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in childrenBrousseau D, Scott J, Badaki-Makun O, Darbari D, Chumpitazi C, Airewele G, Ellison A, Smith-Whitley K, Mahajan P, Sarnaik S, Casper T, Cook L, Dean J, Leonard J, Hulbert M, Powell E, Liem R, Hickey R, Krishnamurti L, Hillery C, Nimmer M, Panepinto J, Network F. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood 2015, 126: 1651-1657. PMID: 26232172, PMCID: PMC4591790, DOI: 10.1182/blood-2015-05-647107.
Sickle Cell Trait Screening of Collegiate Athletes: Ethical Reasons for Program ReformFerrari R, Parker L, Grubs R, Krishnamurti L. Sickle Cell Trait Screening of Collegiate Athletes: Ethical Reasons for Program Reform. Journal Of Genetic Counseling 2015, 24: 873-877. PMID: 26040250, DOI: 10.1007/s10897-015-9849-1.
Development, Content Validity, and User Review of a Web-based Multidimensional Pain Diary for Adolescent and Young Adults With Sickle Cell DiseaseBakshi N, Stinson J, Ross D, Lukombo I, Mittal N, Joshi S, Belfer I, Krishnamurti L. Development, Content Validity, and User Review of a Web-based Multidimensional Pain Diary for Adolescent and Young Adults With Sickle Cell Disease. The Clinical Journal Of Pain 2015, 31: 580-590. PMID: 25565585, DOI: 10.1097/ajp.0000000000000195.
Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid useTelen M, Wun T, McCavit T, De Castro L, Krishnamurti L, Lanzkron S, Hsu L, Smith W, Rhee S, Magnani J, Thackray H. Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use. Blood 2015, 125: 2656-2664. PMID: 25733584, PMCID: PMC4408290, DOI: 10.1182/blood-2014-06-583351.
Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortalityGoel R, Ness P, Takemoto C, Krishnamurti L, King K, Tobian A. Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality. Blood 2015, 125: 1470-1476. PMID: 25588677, PMCID: PMC4342358, DOI: 10.1182/blood-2014-10-605493.
Pan-Selectin Antagonist Rivipansel (GMI-1070) Reduces Soluble E-Selectin Levels While Improving Clinical Outcomes in SCD Vaso-Occlusive CrisisWun T, Telen M, Krishnamurti L, McCavit T, DeCastro L, Flanner H, Kuypers F, Larkin S, Rhee S, Magnani J, Thackray H. Pan-Selectin Antagonist Rivipansel (GMI-1070) Reduces Soluble E-Selectin Levels While Improving Clinical Outcomes in SCD Vaso-Occlusive Crisis. Blood 2014, 124: 2704. DOI: 10.1182/blood.v124.21.2704.2704.
A Multi-Center Randomized Controlled Trial of Intravenous Magnesium for Sickle Cell Pain Crisis in ChildrenBrousseau D, Scott J, Badaki O, Darbari D, Chumpitazi C, Airewele G, Ellison A, Smith-Whitley K, Mahajan P, Sarnaik S, Casper T, Cook L, Dean M, Leonard J, Hulbert M, Powell E, Liem R, Hickey R, Krishnamurti L, Hillery C, Panepinto J. A Multi-Center Randomized Controlled Trial of Intravenous Magnesium for Sickle Cell Pain Crisis in Children. Blood 2014, 124: 88. DOI: 10.1182/blood.v124.21.88.88.
Feasibility and Tolerability of Quantitative Sensory Testing in Patients with Sickle Cell Disease at the End of a Vasoocclusive EpisodeBakshi N, Lukombo I, Belfer I, Krishnamurti L. Feasibility and Tolerability of Quantitative Sensory Testing in Patients with Sickle Cell Disease at the End of a Vasoocclusive Episode. Blood 2014, 124: 3519. DOI: 10.1182/blood.v124.21.3519.3519.
PETIT and PETIT 2: Treatment with Eltrombopag in 171 Children with Chronic Immune Thrombocytopenia (ITP)Bussel J, Grainger J, de Miguel P, Despotovic J, Locatelli F, Chotsampancharoen T, Donyush E, Navarro J, Pongtanakul B, Komvilaisak P, Sosothikul D, Blanchette V, Drelichman G, Krishnamurti L, Sirachainan N, Connor P, David M, Holzhauer S, Lebedev V, Lemons R, Pospisilova D, Ramenghi U, Boayue K, Matthews D, Marcello L, Iyengar M, Chan G, Chagin K, Theodore D, Bakshi K, Bailey C. PETIT and PETIT 2: Treatment with Eltrombopag in 171 Children with Chronic Immune Thrombocytopenia (ITP). Blood 2014, 124: 1450. DOI: 10.1182/blood.v124.21.1450.1450.
Feasibility of a Newborn Screening and Follow-up Programme for Sickle Cell Disease among South Gujarat (India) Tribal PopulationsItalia Y, Krishnamurti L, Mehta V, Raicha B, Italia K, Mehta P, Ghosh K, Colah R. Feasibility of a Newborn Screening and Follow-up Programme for Sickle Cell Disease among South Gujarat (India) Tribal Populations. Journal Of Medical Screening 2014, 22: 1-7. PMID: 25341880, DOI: 10.1177/0969141314557372.
Does e-pain plan improve management of sickle cell disease associated vaso-occlusive pain crisis? A mixed methods evaluationKato-Lin Y, Krishnamurti L, Padman R, Seltman H. Does e-pain plan improve management of sickle cell disease associated vaso-occlusive pain crisis? A mixed methods evaluation. International Journal Of Medical Informatics 2014, 83: 814-824. PMID: 25179666, DOI: 10.1016/j.ijmedinf.2014.08.003.
Prodromal Illness Before Acute Chest Syndrome in Pediatric Patients With Sickle Cell DiseaseCreary S, Krishnamurti L. Prodromal Illness Before Acute Chest Syndrome in Pediatric Patients With Sickle Cell Disease. Journal Of Pediatric Hematology/Oncology 2014, 36: 480-483. PMID: 24633302, DOI: 10.1097/mph.0000000000000146.
Carcinoma-associated retinopathy in a young teenager with immature teratoma of the ovaryTuraka K, Kietz D, Krishnamurti L, Mitchell E, Scanga H, Fu V, Sylvester C. Carcinoma-associated retinopathy in a young teenager with immature teratoma of the ovary. Journal Of American Association For Pediatric Ophthalmology And Strabismus 2014, 18: 396-398. PMID: 25173906, DOI: 10.1016/j.jaapos.2014.03.007.
Reply: Practice Guideline for Pulmonary Hypertension in Sickle Cell: Direct Evidence Needed before Universal AdoptionKlings E, Machado R, Morris C, Gordeuk V, Kato G, Ataga K, Castro O, Hsu L, Telen M, Krishnamurti L, Steinberg M, Gladwin M. Reply: Practice Guideline for Pulmonary Hypertension in Sickle Cell: Direct Evidence Needed before Universal Adoption. American Journal Of Respiratory And Critical Care Medicine 2014, 190: 238-240. PMID: 25025360, PMCID: PMC4226058, DOI: 10.1164/rccm.201404-0733le.
Prevalence of the βS Gene Among Scheduled Castes, Scheduled Tribes and Other Backward Class Groups in Central IndiaShrikhande A, Arjunan A, Agarwal A, Dani A, Tijare J, Gettig E, Krishnamurti L. Prevalence of the βS Gene Among Scheduled Castes, Scheduled Tribes and Other Backward Class Groups in Central India. Hemoglobin 2014, 38: 230-235. PMID: 25023085, DOI: 10.3109/03630269.2014.931287.
Risk Factors for Death in 632 Patients with Sickle Cell Disease in the United States and United KingdomGladwin M, Barst R, Gibbs J, Hildesheim M, Sachdev V, Nouraie M, Hassell K, Little J, Schraufnagel D, Krishnamurti L, Novelli E, Girgis R, Morris C, Rosenzweig E, Badesch D, Lanzkron S, Castro O, Taylor J, Goldsmith J, Kato G, Gordeuk V, Machado R, Investigators and Patients O. Risk Factors for Death in 632 Patients with Sickle Cell Disease in the United States and United Kingdom. PLOS ONE 2014, 9: e99489. PMID: 24988120, PMCID: PMC4079316, DOI: 10.1371/journal.pone.0099489.
Impact of individualized pain plan on the emergency management of children with sickle cell diseaseKrishnamurti L, Smith‐Packard B, Gupta A, Campbell M, Gunawardena S, Saladino R. Impact of individualized pain plan on the emergency management of children with sickle cell disease. Pediatric Blood & Cancer 2014, 61: 1747-1753. PMID: 24962217, DOI: 10.1002/pbc.25024.
Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trialHelton KJ, Adams R, Kesler K, Lockhart A, Aygun B, Driscoll C, Heeney M, Jackson S, Krishnamurti L, Miller S, Sarnaik S, Schultz W, Ware R, Investigators F. Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood 2014, 124: 891-898. PMID: 24914136, PMCID: PMC4126329, DOI: 10.1182/blood-2013-12-545186.
An Electronic Six-Minute Walk Test Platform for Clinical ApplicationsBai Y, Krishnamurti L, Jia W, Mao Z, Sun M. An Electronic Six-Minute Walk Test Platform for Clinical Applications. 2014, 1-2. DOI: 10.1109/nebec.2014.6972715.
An Official American Thoracic Society Clinical Practice Guideline: Diagnosis, Risk Stratification, and Management of Pulmonary Hypertension of Sickle Cell DiseaseKlings E, Machado R, Barst R, Morris C, Mubarak K, Gordeuk V, Kato G, Ataga K, Gibbs J, Castro O, Rosenzweig E, Sood N, Hsu L, Wilson K, Telen M, Decastro L, Krishnamurti L, Steinberg M, Badesch D, Gladwin M. An Official American Thoracic Society Clinical Practice Guideline: Diagnosis, Risk Stratification, and Management of Pulmonary Hypertension of Sickle Cell Disease. American Journal Of Respiratory And Critical Care Medicine 2014, 189: 727-740. PMID: 24628312, PMCID: PMC3983842, DOI: 10.1164/rccm.201401-0065st.
A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickle‐cell diseaseCreary S, Gladwin M, Byrne M, Hildesheim M, Krishnamurti L. A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickle‐cell disease. Pediatric Blood & Cancer 2014, 61: 1068-1073. PMID: 24436121, DOI: 10.1002/pbc.24931.
Comprehensive integrated care for patients with sickle cell disease in a remote aboriginal tribal population in southern IndiaNimgaonkar V, Krishnamurti L, Prabhakar H, Menon N. Comprehensive integrated care for patients with sickle cell disease in a remote aboriginal tribal population in southern India. Pediatric Blood & Cancer 2013, 61: 702-705. PMID: 24347362, DOI: 10.1002/pbc.24723.
First Successful Lung Transplantation for Sickle Cell Disease with Severe Pulmonary Arterial Hypertension and Pulmonary Veno‐Occlusive DiseaseGeorge M, Novelli E, Shigemura N, Simon M, Feingold B, Krishnamurti L, Morrell M, Gries C, Haider S, Johnson B, Crespo M, Bhama J, Bermudez C, Yousem S, Toyoda Y, Champion H, Pilewski J, Gladwin M. First Successful Lung Transplantation for Sickle Cell Disease with Severe Pulmonary Arterial Hypertension and Pulmonary Veno‐Occlusive Disease. Pulmonary Circulation 2013, 3: 952-958. PMID: 25006411, PMCID: PMC4070828, DOI: 10.1086/674749.
Is intensive monitoring during the first transfusion in pediatric patients necessary?Berg A, Courtney R, Krishnamurti L, Triulzi D, Yazer M. Is intensive monitoring during the first transfusion in pediatric patients necessary? Hematology 2013, 19: 304-308. PMID: 24074624, DOI: 10.1179/1607845413y.0000000122.
Development, Establishment Of the Psychometric Properties and Usability Testing Of a Novel Multi-Dimensional Web Based Diary For Children With Sickle Cell DiseaseBakshi N, Stinson J, Lukombo I, Ross D, Mittal N, Joshi S, Krishnamurti L. Development, Establishment Of the Psychometric Properties and Usability Testing Of a Novel Multi-Dimensional Web Based Diary For Children With Sickle Cell Disease. Blood 2013, 122: 2961. DOI: 10.1182/blood.v122.21.2961.2961.
An Analysis Of The Pediatric Sub-Group From The Phase 2 Study Of GMI 1070 – A Novel Agent For The Vaso-Occlusive Crisis Of Sickle Cell AnemiaMcCavit T, Krishnamurti L, Hsu L, Quinn C, Odame I, Alvarez O, Driscoll C, Smith-Whitley K, Rhee S, Wun T, Telen M, Thackray H. An Analysis Of The Pediatric Sub-Group From The Phase 2 Study Of GMI 1070 – A Novel Agent For The Vaso-Occlusive Crisis Of Sickle Cell Anemia. Blood 2013, 122: 2206. DOI: 10.1182/blood.v122.21.2206.2206.
GMI 1070: Reduction In Time To Resolution Of Vaso-Occlusive Crisis and Decreased Opioid Use In a Prospective, Randomized, Multi-Center Double Blind, Adaptive Phase 2 Study In Sickle Cell DiseaseTelen M, Wun T, McCavit T, De Castro L, Krishnamurti L, Lanzkron S, Hsu L, Smith W, Rhee S, Magnani J, Thackray H. GMI 1070: Reduction In Time To Resolution Of Vaso-Occlusive Crisis and Decreased Opioid Use In a Prospective, Randomized, Multi-Center Double Blind, Adaptive Phase 2 Study In Sickle Cell Disease. Blood 2013, 122: 776. DOI: 10.1182/blood.v122.21.776.776.
Catastrophizing and Depression Are Associated With a Poorer Quality Of Life In Pediatric Patients With Sickle Cell DiseaseBakshi N, Lukombo I, Shnol H, Mittal N, Joshi S, Belfer I, Krishnamurti L. Catastrophizing and Depression Are Associated With a Poorer Quality Of Life In Pediatric Patients With Sickle Cell Disease. Blood 2013, 122: 1706. DOI: 10.1182/blood.v122.21.1706.1706.
Long Term Safety and Efficacy Of Low Fixed Dose Hydroxyurea In Pediatric Patients With Sickle Cell Anemia: A Single Center Study From Central IndiaJain D, Krishnamurti L, Sarathi V, Desai S, Gokhale A. Long Term Safety and Efficacy Of Low Fixed Dose Hydroxyurea In Pediatric Patients With Sickle Cell Anemia: A Single Center Study From Central India. Blood 2013, 122: 1000. DOI: 10.1182/blood.v122.21.1000.1000.
A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell diseaseWun T, Soulieres D, Frelinger A, Krishnamurti L, Novelli E, Kutlar A, Ataga K, Knupp C, McMahon L, Strouse J, Zhou C, Heath L, Nwachuku C, Jakubowski J, Riesmeyer J, Winters K. A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease. Journal Of Hematology & Oncology 2013, 6: 17. PMID: 23414938, PMCID: PMC3585853, DOI: 10.1186/1756-8722-6-17.
Analysis of national and single-center incidence and survival after liver transplantation for hepatoblastoma: New trends and future opportunitiesCruz R, Ranganathan S, Mazariegos G, Soltys K, Nayyar N, Sun Q, Bond G, Shaw P, Haberman K, Krishnamurti L, Marsh J, Humar A, Sindhi R. Analysis of national and single-center incidence and survival after liver transplantation for hepatoblastoma: New trends and future opportunities. Surgery 2013, 153: 150-159. PMID: 23331862, DOI: 10.1016/j.surg.2012.11.006.
Feasibility of Electronic Directly Observed Therapy for Pediatric Leukemia PatientsCohen A, Krishnamurti L, Creary S. Feasibility of Electronic Directly Observed Therapy for Pediatric Leukemia Patients. Blood 2012, 120: 3538. DOI: 10.1182/blood.v120.21.3538.3538.
Risk Factors for Death in 632 Patients with Sickle Cell Anemia in the United States and United KingdomGladwin M, Barst R, Gibbs J, Hildesheim M, Sachdev V, Nouraie M, Hassell K, Little J, Schraufnagel D, Krishnamurti L, Novelli E, Girgis R, Zhang Y, Morris C, Rosenzweig E, Badesch D, Lanzkron S, Castro O, Taylor J, Goldsmith J, Gordeuk V, Kato G, Machado R. Risk Factors for Death in 632 Patients with Sickle Cell Anemia in the United States and United Kingdom. Blood 2012, 120: 3240. DOI: 10.1182/blood.v120.21.3240.3240.
Mobile Directly Observed Therapy: Monitoring and Improving Hydroxyurea Adherence in Pediatric Sickle Cell PatientsCreary S, Gladwin M, Krishnamurti L. Mobile Directly Observed Therapy: Monitoring and Improving Hydroxyurea Adherence in Pediatric Sickle Cell Patients. Blood 2012, 120: 2060. DOI: 10.1182/blood.v120.21.2060.2060.
The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and EuropeNouraie M, Lee J, Zhang Y, Kanias T, Zhao X, Xiong Z, Oriss T, Zeng Q, Kato G, Gibbs J, Hildesheim M, Sachdev V, Barst R, Machado R, Hassell K, Little J, Schraufnagel D, Krishnamurti L, Novelli E, Girgis R, Morris C, Rosenzweig E, Badesch D, Lanzkron S, Castro O, Goldsmith J, Gordeuk V, Gladwin M. The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe. Haematologica 2012, 98: 464-472. PMID: 22983573, PMCID: PMC3659937, DOI: 10.3324/haematol.2012.068965.
Mortality, health care utilization and associated diagnoses in hospitalized patients with haemophilia in the United States: first reported nationwide estimatesGOEL R, KRISHNAMURTI L. Mortality, health care utilization and associated diagnoses in hospitalized patients with haemophilia in the United States: first reported nationwide estimates. Haemophilia 2012, 18: 688-692. PMID: 22500777, DOI: 10.1111/j.1365-2516.2012.02774.x.
A Novel TCIRG1 Gene Mutation Leads to Severe Osteopetrosis with Altered Content of Monocytes/Macrophages in Several OrgansGheorghe G, Galambos C, Jain S, Krishnamurti L, Jaffe R. A Novel TCIRG1 Gene Mutation Leads to Severe Osteopetrosis with Altered Content of Monocytes/Macrophages in Several Organs. Pediatric And Developmental Pathology 2012, 15: 156-159. PMID: 22280207, DOI: 10.2350/11-05-1032-cr.1.
Oocyte cryopreservation in a patient with sickle cell disease prior to hematopoietic stem cell transplantation: first reportDovey S, Krishnamurti L, Sanfilippo J, Gunawardena S, Mclendon P, Campbell M, Alway S, Efymow B, Gracia C. Oocyte cryopreservation in a patient with sickle cell disease prior to hematopoietic stem cell transplantation: first report. Journal Of Assisted Reproduction And Genetics 2012, 29: 265-269. PMID: 22219083, PMCID: PMC3288130, DOI: 10.1007/s10815-011-9698-2.
13 HematologyWetzler M, Brown P, Hunger S, Sheppard C, Hillyer C, Guinan E, Rodriguez N, Jamieson K, Morales-Arias J, Pietrangelo A, Chitlur M, Kulkarni R, Carpenter S, Mazloom A, Paulman P, Kyle R, Rajkumar S, Shammo J, Bonilla M, Evens A, Cornett P, Andrès E, Sood S, Abrams C, Duggan P, Pierach C, Novelli E, Gladwin M, Krishnamurti L, Holstein S, Hohl R, Millward P, Brecher M, Kiss J. 13 Hematology. 2012, 767-871. DOI: 10.1016/b978-1-4557-0738-6.00013-9.
Clinical trial implementation and recruitment: Lessons learned from the early closure of a randomized clinical trialPeters-Lawrence M, Bell M, Hsu L, Osunkwo I, Seaman P, Blackwood M, Guillaume E, Bellevue R, Krishnamurti L, Smith W, Dampier C, Minniti C, Network F. Clinical trial implementation and recruitment: Lessons learned from the early closure of a randomized clinical trial. Contemporary Clinical Trials 2011, 33: 291-297. PMID: 22155024, PMCID: PMC3577351, DOI: 10.1016/j.cct.2011.11.018.
A Randomized, Double-Blind, Adaptive Phase 2 Multi-Center Study of Prasugrel Compared to Placebo in Adults with Sickle Cell DiseaseWun T, Soulieres D, Krishnamurti L, Kutlar A, Ataga K, Zhou C, Heath L, Nwachuku C, Jakubowski J, Winters K, Riesmeyer J. A Randomized, Double-Blind, Adaptive Phase 2 Multi-Center Study of Prasugrel Compared to Placebo in Adults with Sickle Cell Disease. Blood 2011, 118: 847. DOI: 10.1182/blood.v118.21.847.847.
Association of Genetic Variation in the Catechol-O-Methyl Transferase Gene with Pain and Six Minute Walk Distance in Sickle Cell Anemia Patients From the Walk-PHaSST StudyZhang Y, Zeng Q, Belfer I, Goel R, Porter M, Chu Y, Barst R, Hassell K, Machado R, Goldsmith J, Gladwin M, Krishnamurti L. Association of Genetic Variation in the Catechol-O-Methyl Transferase Gene with Pain and Six Minute Walk Distance in Sickle Cell Anemia Patients From the Walk-PHaSST Study. Blood 2011, 118: 1075. DOI: 10.1182/blood.v118.21.1075.1075.
Non-Cardiopulmonary Factors Affecting the Six-Minute Walk Distance in Patients with Sickle Cell Disease: Results From the Walk-PHaSST StudyGoel R, Hassell K, Machado R, Barst R, Yovetich N, Kato G, Gordeuk V, Little J, Gibbs J, Schraufnagel D, Girgis R, Rosenzweig E, Morris C, Badesch D, Lanzkron S, Onyekwere O, Nouraie M, Castro O, Sachdev V, Waclawiw M, Woolson R, Goldsmith J, Gladwin M, Krishnamurti L. Non-Cardiopulmonary Factors Affecting the Six-Minute Walk Distance in Patients with Sickle Cell Disease: Results From the Walk-PHaSST Study. Blood 2011, 118: 1074. DOI: 10.1182/blood.v118.21.1074.1074.
Clinical Predictors of All-Cause In-Hospital Mortality In Patients with Sickle Cell Disease in the United States- First Reported Results From A Nationally Representative SampleGoel R, Gupta A, Krishnamurti L. Clinical Predictors of All-Cause In-Hospital Mortality In Patients with Sickle Cell Disease in the United States- First Reported Results From A Nationally Representative Sample. Blood 2011, 118: 339. DOI: 10.1182/blood.v118.21.339.339.
Echocardiographic Markers of Elevated Pulmonary Pressure and Left Ventricular Diastolic Dysfunction Are Associated With Exercise Intolerance in Adults and Adolescents With Homozygous Sickle Cell Anemia in the United States and United KingdomSachdev V, Kato G, Gibbs J, Barst R, Machado R, Nouraie M, Hassell K, Little J, Schraufnagel D, Krishnamurti L, Novelli E, Girgis R, Morris C, Rosenzweig E, Badesch D, Lanzkron S, Castro O, Taylor J, Hannoush H, Goldsmith J, Gladwin M, Gordeuk V. Echocardiographic Markers of Elevated Pulmonary Pressure and Left Ventricular Diastolic Dysfunction Are Associated With Exercise Intolerance in Adults and Adolescents With Homozygous Sickle Cell Anemia in the United States and United Kingdom. Circulation 2011, 124: 1452-1460. PMID: 21900080, PMCID: PMC3183314, DOI: 10.1161/circulationaha.111.032920.
Attitudes and Beliefs of African‐Americans Toward Genetics, Genetic Testing, and Sickle Cell Disease Education and AwarenessLong K, Thomas S, Grubs R, Gettig E, Krishnamurti L. Attitudes and Beliefs of African‐Americans Toward Genetics, Genetic Testing, and Sickle Cell Disease Education and Awareness. Journal Of Genetic Counseling 2011, 20: 572-592. PMID: 21748660, DOI: 10.1007/s10897-011-9388-3.
Genetic counseling following the detection of hemoglobinopathy trait on the newborn screen is well received, improves knowledge, and relieves anxietyKladny B, Williams A, Gupta A, Gettig E, Krishnamurti L. Genetic counseling following the detection of hemoglobinopathy trait on the newborn screen is well received, improves knowledge, and relieves anxiety. Genetics In Medicine 2011, 13: 658-661. PMID: 21546841, DOI: 10.1097/gim.0b013e31821435f7.
Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacityMachado R, Barst R, Yovetich N, Hassell K, Kato G, Gordeuk V, Gibbs J, Little J, Schraufnagel D, Krishnamurti L, Girgis R, Morris C, Rosenzweig E, Badesch D, Lanzkron S, Onyekwere O, Castro O, Sachdev V, Waclawiw M, Woolson R, Goldsmith J, Gladwin M. Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood 2011, 118: 855-864. PMID: 21527519, PMCID: PMC3148167, DOI: 10.1182/blood-2010-09-306167.
Testing of Collegiate Athletes for Sickle Cell Trait: What We, as Genetic Counselors Should KnowAloe A, Krishnamurti L, Kladny B. Testing of Collegiate Athletes for Sickle Cell Trait: What We, as Genetic Counselors Should Know. Journal Of Genetic Counseling 2011, 20: 337-340. PMID: 21503822, DOI: 10.1007/s10897-011-9366-9.
Nitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain Crisis: A Randomized Controlled TrialGladwin M, Kato G, Weiner D, Onyekwere O, Dampier C, Hsu L, Hagar R, Howard T, Nuss R, Okam M, Tremonti C, Berman B, Villella A, Krishnamurti L, Lanzkron S, Castro O, Gordeuk V, Coles W, Peters-Lawrence M, Nichols J, Hall M, Hildesheim M, Blackwelder W, Baldassarre J, Casella J, Investigators F. Nitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain Crisis: A Randomized Controlled Trial. JAMA 2011, 305: 893-902. PMID: 21364138, PMCID: PMC3403835, DOI: 10.1001/jama.2011.235.
A Pilot Study of Pharmacokinetics-Based Mycophenolate Mofetil Dosing for Acute Graft-Versus-Host-Disease ProphylaxisWindreich R, Venkataramanan R, Howrie D, Krishnamurti L, Goyal R. A Pilot Study of Pharmacokinetics-Based Mycophenolate Mofetil Dosing for Acute Graft-Versus-Host-Disease Prophylaxis. Transplantation And Cellular Therapy 2011, 17: s344-s345. DOI: 10.1016/j.bbmt.2010.12.570.
Predictors of Six-Minute Walk Distance In Adults with Sickle Cell Anemia In the Walk-PHaSST StudyBarst R, Kato G, Sachdev V, Nouraie M, Machado R, Hassell K, Gibbs S, Little J, Schraufnagel D, Krishnamurti L, Girgis R, Morris C, Badesch D, Lanzkron S, Castro O, Rosenzweig E, Goldsmith J, Gladwin M, Gordeuk V. Predictors of Six-Minute Walk Distance In Adults with Sickle Cell Anemia In the Walk-PHaSST Study. Blood 2010, 116: 947. DOI: 10.1182/blood.v116.21.947.947.
Cigarette Smoking Is An Independent Predictor of Chronic Pain In Sickle Cell Patients: Results From the Walk-PHaSST StudyGoel R, Hassell K, Castro O, Barst R, Rosenzweig E, Sachdev V, Machado R, Gibbs S, Little J, Schraufnagel D, Girgis R, Morris C, Badesch D, Lanzkron S, Goldsmith J, Gordeuk V, Kato G, Gladwin M, Krishnamurti L. Cigarette Smoking Is An Independent Predictor of Chronic Pain In Sickle Cell Patients: Results From the Walk-PHaSST Study. Blood 2010, 116: 4804. DOI: 10.1182/blood.v116.21.4804.4804.
Platelet Transfusions In Patients with Immune Thrombocytopenic Purpura (ITP) – Evaluation of the Current Nationwide Inpatient Hospital Practices.Tran L, Goel R, Krishnamurti L. Platelet Transfusions In Patients with Immune Thrombocytopenic Purpura (ITP) – Evaluation of the Current Nationwide Inpatient Hospital Practices. Blood 2010, 116: 3809. DOI: 10.1182/blood.v116.21.3809.3809.
Chronic Pain Is An Independent Predictor of Lower 6 Minute Walk Distance In Patients with Sickle Cell Disease: Results From Walk-PHaSST StudyKrishnamurti L, Goel R, Castro O, Barst R, Rosenzweig E, Sachdev V, Machado R, Gibbs S, Little J, Schraufnagel D, Girgis R, Morris C, Badesch D, Lanzkron S, Goldsmith J, Gordeuk V, Kato G, Gladwin M, Hassell K. Chronic Pain Is An Independent Predictor of Lower 6 Minute Walk Distance In Patients with Sickle Cell Disease: Results From Walk-PHaSST Study. Blood 2010, 116: 2658. DOI: 10.1182/blood.v116.21.2658.2658.
Long-Term Follow-up of Adults with Severe Sickle Cell Disease After Hematopoietic Stem Cell Transplantation Using Reduced Intensity ConditioningBiernacki M, Okam M, Shenoy S, Krishnamurti L, Horwitz M, Neuberg D, Antin J, Wu C. Long-Term Follow-up of Adults with Severe Sickle Cell Disease After Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning. Blood 2010, 116: 261. DOI: 10.1182/blood.v116.21.261.261.
Prolonged QTc Interval Is Common In Patients with Sickle Cell Disease and Has An Inverse Relationship to Hemoglobin and Hematocrit: Results From CSSCDGoel R, Rajderkar S, Padman R, Krishnamurti L. Prolonged QTc Interval Is Common In Patients with Sickle Cell Disease and Has An Inverse Relationship to Hemoglobin and Hematocrit: Results From CSSCD. Blood 2010, 116: 2675. DOI: 10.1182/blood.v116.21.2675.2675.
Lack of Difference In Co-Morbidities Associated with Deep Venous Thrombosis In Patients Undergoing Total Knee ReplacementViswanathan P, Tiwari U, Krishnamurti L. Lack of Difference In Co-Morbidities Associated with Deep Venous Thrombosis In Patients Undergoing Total Knee Replacement. Blood 2010, 116: 2578. DOI: 10.1182/blood.v116.21.2578.2578.
Burden of In-Hospital Care of Thrombotic Microangiopathies In the United StatesGupta A, Krishnamurti L. Burden of In-Hospital Care of Thrombotic Microangiopathies In the United States. Blood 2010, 116: 2559. DOI: 10.1182/blood.v116.21.2559.2559.
NT-Probnp as a Marker of Cardiopulmonary Compromise and Exercise Limitation In Adults with Sickle Cell Anemia In the Walk-PHaSST StudyNouraie M, Barst R, Rosenzweig E, Sachdev V, Machado R, Hassell K, Gibbs J, Little J, Schraufnagel D, Krishnamurti L, Novelli E, Girgis R, Morris C, Badesch D, Lanzkron S, Castro O, Goldsmith J, Gladwin M, Gordeuk V, Kato G. NT-Probnp as a Marker of Cardiopulmonary Compromise and Exercise Limitation In Adults with Sickle Cell Anemia In the Walk-PHaSST Study. Blood 2010, 116: 1639. DOI: 10.1182/blood.v116.21.1639.1639.
Does Deep Venous Thrombosis as Primary Admitting Diagnosis Represent Different Etiologies and Disease Processes as Compared to DVT as Secondary Diagnoses (SD)?Viswanathan P, Gandhi T, Krishnamurti L. Does Deep Venous Thrombosis as Primary Admitting Diagnosis Represent Different Etiologies and Disease Processes as Compared to DVT as Secondary Diagnoses (SD)? Blood 2010, 116: 1540. DOI: 10.1182/blood.v116.21.1540.1540.
Changing Age Distribution of Deep Venous Thrombosis In the United StatesViswanathan P, Krishnamurti L. Changing Age Distribution of Deep Venous Thrombosis In the United States. Blood 2010, 116: 1539. DOI: 10.1182/blood.v116.21.1539.1539.
Evaluation Of Sildenafil Therapy For Patients With Sickle Cell Disease And Increased Tricuspid Regurgitant Velocity: Preliminary Results Of The Walk-PHaSST TrialMachado R, Barst R, Yovetich N, Hassell K, Goldsmith J, Woolson R, Gordeuk V, Gibbs S, Little J, Kato G, Schraufnagel D, Krishnamurti L, Girgis R, Morris C, Berman-Rosenzweig E, Badesch D, Waclawiw M, Gladwin M. Evaluation Of Sildenafil Therapy For Patients With Sickle Cell Disease And Increased Tricuspid Regurgitant Velocity: Preliminary Results Of The Walk-PHaSST Trial. 2010, a2514-a2514. DOI: 10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a2514.
Hematopoietic Stem Cell Transplantation for Hemoglobinopathies: Current Practice and Emerging TrendsSmiers F, Krishnamurti L, Lucarelli G. Hematopoietic Stem Cell Transplantation for Hemoglobinopathies: Current Practice and Emerging Trends. Pediatric Clinics Of North America 2010, 57: 181-205. PMID: 20307718, DOI: 10.1016/j.pcl.2010.01.003.
Safety and Efficacy of Sildenafil Therapy for Doppler-Defined Pulmonary Hypertension in Patients with Sickle Cell Disease: Preliminary Results of the Walk-PHaSST Clinical Trial.Machado R, Barst R, Yovetich N, Hassell K, Goldsmith J, Woolson R, Gordeuk V, Gibbs S, Little J, Kato G, Schraufnagel D, Krishnamurti L, Girgis R, Morris C, Berman-Rosenzweig E, Badesch D, Waclawiw M, Gladwin M. Safety and Efficacy of Sildenafil Therapy for Doppler-Defined Pulmonary Hypertension in Patients with Sickle Cell Disease: Preliminary Results of the Walk-PHaSST Clinical Trial. Blood 2009, 114: 571. DOI: 10.1182/blood.v114.22.571.571.
National Healthcare Utilization Trends for Deep Vein Thrombosis in the United States.Viswanathan P, Goswami U, Krishnamurti L. National Healthcare Utilization Trends for Deep Vein Thrombosis in the United States. Blood 2009, 114: 3183. DOI: 10.1182/blood.v114.22.3183.3183.
Current Epidemiology and Hospitalization Characteristics for Acute Chest Syndrome: A Nationally Representative Survey.Goel R, Viswanathan P, Krishnamurti L. Current Epidemiology and Hospitalization Characteristics for Acute Chest Syndrome: A Nationally Representative Survey. Blood 2009, 114: 4608. DOI: 10.1182/blood.v114.22.4608.4608.
National Burden of Emergency Department Care for Sickle Disease: Impact of Age, Insurance Status, Income, Hospital Type and Location On Subsequent Hospital Admission.Goel R, Viswanathan P, Krishnamurti L. National Burden of Emergency Department Care for Sickle Disease: Impact of Age, Insurance Status, Income, Hospital Type and Location On Subsequent Hospital Admission. Blood 2009, 114: 2488. DOI: 10.1182/blood.v114.22.2488.2488.
Severe Sickle Cell Disease—Pathophysiology and TherapyBuchanan G, Vichinsky E, Krishnamurti L, Shenoy S. Severe Sickle Cell Disease—Pathophysiology and Therapy. Transplantation And Cellular Therapy 2009, 16: s64-s67. PMID: 19819341, PMCID: PMC2832723, DOI: 10.1016/j.bbmt.2009.10.001.
Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS)Rao V, Price S, Perkins K, Aldridge P, Tretler J, Davis J, Dale J, Gill F, Hartman K, Stork L, Gnarra D, Krishnamurti L, Newburger P, Puck J, Fleisher T. Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS). Pediatric Blood & Cancer 2009, 52: 847-852. PMID: 19214977, PMCID: PMC2774763, DOI: 10.1002/pbc.21965.
Stable Long-Term Donor Engraftment following Reduced-Intensity Hematopoietic Cell Transplantation for Sickle Cell DiseaseKrishnamurti L, Kharbanda S, Biernacki M, Zhang W, Baker K, Wagner J, Wu C. Stable Long-Term Donor Engraftment following Reduced-Intensity Hematopoietic Cell Transplantation for Sickle Cell Disease. Transplantation And Cellular Therapy 2008, 14: 1270-1278. PMID: 18940682, DOI: 10.1016/j.bbmt.2008.08.016.
Iron-Deficiency AnemiaKrishnamurti L. Iron-Deficiency Anemia. 2008, 2201-2211. DOI: 10.1542/9781581106411-9-ch287.
Hematopoietic stem cell transplantation for hemoglobinopathies: Progress and prospectsKrishnamurti L, Gupta D. Hematopoietic stem cell transplantation for hemoglobinopathies: Progress and prospects. Indian Journal Of Medical And Paediatric Oncology 2008, 29: 39-48. DOI: 10.4103/0971-5851.51444.
Hematopoietic Cell Transplantation for HemoglobinopathiesKrishnamurti L, Bunn H, Williams A, Tolar J. Hematopoietic Cell Transplantation for Hemoglobinopathies. Current Problems In Pediatric And Adolescent Health Care 2008, 38: 6-18. PMID: 18068866, DOI: 10.1016/j.cppeds.2007.10.002.
Use of Rituximab for Refractory Immune Cytopenias Associated with Autoimmune Lymphoproliferative Syndrome (ALPS).Dale J, Price S, Tretler J, Aldridge P, Montague S, Davis J, Gill F, Hartman K, Stork L, Gnarra D, Krishnamurti L, Puck J, Fleisher T, Rao V. Use of Rituximab for Refractory Immune Cytopenias Associated with Autoimmune Lymphoproliferative Syndrome (ALPS). Blood 2007, 110: 1319. DOI: 10.1182/blood.v110.11.1319.1319.
Unrelated cord blood transplantation in children with sickle cell disease: Review of four‐center experienceAdamkiewicz T, Szabolcs P, Haight A, Baker K, Staba S, Kedar A, Chiang K, Krishnamurti L, Boyer M, Kurtzberg J, Wagner J, Wingard J, Yeager A. Unrelated cord blood transplantation in children with sickle cell disease: Review of four‐center experience. Pediatric Transplantation 2007, 11: 641-644. PMID: 17663687, DOI: 10.1111/j.1399-3046.2007.00725.x.
Health beliefs among African American women regarding genetic testing and counseling for sickle cell diseaseGustafson S, Gettig E, Watt-Morse M, Krishnamurti L. Health beliefs among African American women regarding genetic testing and counseling for sickle cell disease. Genetics In Medicine 2007, 9: 303-310. PMID: 17505208, DOI: 10.1097/gim.0b013e3180534282.
Hematopoietic cell transplantation for sickle cell disease: state of the artKrishnamurti L. Hematopoietic cell transplantation for sickle cell disease: state of the art. Expert Opinion On Biological Therapy 2007, 7: 161-172. PMID: 17250455, DOI: 10.1517/14712598.7.2.161.
HEMATOPOIETIC CELL TRANSPLANTATION: A Curative Option for Sickle Cell DiseaseKrishnamurti L. HEMATOPOIETIC CELL TRANSPLANTATION: A Curative Option for Sickle Cell Disease. Pediatric Hematology And Oncology 2007, 24: 569-575. PMID: 18092247, DOI: 10.1080/08880010701640531.
Acute renal failure from xanthine nephropathy during management of acute leukemiaLaRosa C, McMullen L, Bakdash S, Ellis D, Krishnamurti L, Wu H, Moritz M. Acute renal failure from xanthine nephropathy during management of acute leukemia. Pediatric Nephrology 2006, 22: 132-135. PMID: 17039332, DOI: 10.1007/s00467-006-0287-z.
Structured telephone‐based outreach using nonmedical personnel can improve adherence to comprehensive care in families of children with sickle cell diseasePatik M, Phillips L, Kladny B, Captain A, Gettig E, Krishnamurti L. Structured telephone‐based outreach using nonmedical personnel can improve adherence to comprehensive care in families of children with sickle cell disease. American Journal Of Hematology 2006, 81: 462-464. PMID: 16680738, DOI: 10.1002/ajh.20605.
Life threatening parvovirus B19 and herpes simplex virus associated acute myocardial dysfunction in a child with homozygous sickle cell diseaseKrishnamurti L, Lanford L, Munoz R. Life threatening parvovirus B19 and herpes simplex virus associated acute myocardial dysfunction in a child with homozygous sickle cell disease. Pediatric Blood & Cancer 2006, 49: 1019-1021. PMID: 16700044, DOI: 10.1002/pbc.20855.
Elevation of tricuspid regurgitant jet velocity, a marker for pulmonary hypertension in children with sickle cell diseaseAmbrusko S, Gunawardena S, Sakara A, Windsor B, Lanford L, Michelson P, Krishnamurti L. Elevation of tricuspid regurgitant jet velocity, a marker for pulmonary hypertension in children with sickle cell disease. Pediatric Blood & Cancer 2006, 47: 907-913. PMID: 16496290, DOI: 10.1002/pbc.20791.
Stable donor engraftment following reduced intensity hematopoietic cell transplantation for sickle cell diseaseKrishnamurti L, Wu C, Baker S, Wagner J. Stable donor engraftment following reduced intensity hematopoietic cell transplantation for sickle cell disease. Transplantation And Cellular Therapy 2006, 12: 39. DOI: 10.1016/j.bbmt.2005.11.122.
Commentary on “Identification of Unrelated Cord Blood Units for Hematopoietic Stem Cell Transplantation in Children With Sickle Cell Disease”Krishnamurti L. Commentary on “Identification of Unrelated Cord Blood Units for Hematopoietic Stem Cell Transplantation in Children With Sickle Cell Disease”. Journal Of Pediatric Hematology/Oncology 2006, 28: 1-3. PMID: 16394884, DOI: 10.1097/01.mph.0000196448.99446.0a.
Pulmonary Hypertension in Children with Sickle Cell Disease: Clinical Characteristics and Co-Morbidities.Ambrusko S, Gunawardena S, Sakara A, Windsor B, Lanford L, Michelson P, Krishnamurti L. Pulmonary Hypertension in Children with Sickle Cell Disease: Clinical Characteristics and Co-Morbidities. Blood 2005, 106: 3791. DOI: 10.1182/blood.v106.11.3791.3791.
Matched Sibling Donor Hematopoietic Cell Transplantation for Sickle Cell Disease Using a Reduced Intensity Conditioning Regimen Can Lead To Stable Long Term Engraftment.Krishnamurti L, Wu C, Baker K, Wagner J. Matched Sibling Donor Hematopoietic Cell Transplantation for Sickle Cell Disease Using a Reduced Intensity Conditioning Regimen Can Lead To Stable Long Term Engraftment. Blood 2005, 106: 3172. DOI: 10.1182/blood.v106.11.3172.3172.
Mixed Hematopoietic Chimerism for Sickle Cell Disease Prevents Intravascular Hemolysis and Corrects Biomarkers of Endothelial Function.Wu C, Krishnamurti L, Gladwin M, Biernacki M, Rogers S, Wang X, Zahrieh D, Antin J, Ritz J. Mixed Hematopoietic Chimerism for Sickle Cell Disease Prevents Intravascular Hemolysis and Corrects Biomarkers of Endothelial Function. Blood 2005, 106: 2333. DOI: 10.1182/blood.v106.11.2333.2333.
Unrelated Cord Blood Transplantation (UCBT) in Children with Sickle Cell Disease (SCD): US Centers Experience.Adamkiewicz T, Haight A, Mazur M, Baker K, Szabolcs P, Kedar A, Chiang K, Krishnamurti L, Wagner J, Wingard J, Yeager A. Unrelated Cord Blood Transplantation (UCBT) in Children with Sickle Cell Disease (SCD): US Centers Experience. Blood 2005, 106: 2044. DOI: 10.1182/blood.v106.11.2044.2044.
Stable long term engraftment and amelioration of clinical phenotype following hematopoietic stem cell transplantation from a matched sibling donor for sickle cell disease using a reduced intensity conditioning regimenKrishnamurti L, Wu C, Baker S, Yeager A, Wagner J. Stable long term engraftment and amelioration of clinical phenotype following hematopoietic stem cell transplantation from a matched sibling donor for sickle cell disease using a reduced intensity conditioning regimen. Transplantation And Cellular Therapy 2005, 11: 28. DOI: 10.1016/j.bbmt.2004.12.080.
Systematic follow-up and case management of the abnormal newborn screen can improve acceptance of genetic counseling for sickle cell or other hemoglobinopathy traitKladny B, Gettig E, Krishnamurti L. Systematic follow-up and case management of the abnormal newborn screen can improve acceptance of genetic counseling for sickle cell or other hemoglobinopathy trait. Genetics In Medicine 2005, 7: 139-142. PMID: 15714082, DOI: 10.1097/01.gim.0000153662.88425.68.
Ineffective erythropoiesis in recipient precursor cells following non-myeloablative stem cell transplantation in patients with severe sickle cell anemiaWu C, Rogers S, Kutok J, Krishnamurti L, Hochberg E, Biernacki M, Antin J, Ritz J. Ineffective erythropoiesis in recipient precursor cells following non-myeloablative stem cell transplantation in patients with severe sickle cell anemia. Transplantation And Cellular Therapy 2004, 10: 41. DOI: 10.1016/j.bbmt.2003.12.191.
Management of Sickle Cell Disease in Primary CareWilson R, Krishnamurti L, Kamat D. Management of Sickle Cell Disease in Primary Care. Clinical Pediatrics 2003, 42: 753-761. PMID: 14686547, DOI: 10.1177/000992280304200901.
Availability of unrelated donors for hematopoietic stem cell transplantation for hemoglobinopathiesKrishnamurti L, Abel S, Maiers M, Flesch S. Availability of unrelated donors for hematopoietic stem cell transplantation for hemoglobinopathies. Bone Marrow Transplantation 2003, 31: 547-550. PMID: 12692619, DOI: 10.1038/sj.bmt.1703887.
Mutations in the VHL gene in sporadic apparently congenital polycythemiaPastore Y, Jelinek J, Ang S, Guan Y, Liu E, Jedlickova K, Krishnamurti L, Prchal J. Mutations in the VHL gene in sporadic apparently congenital polycythemia. Blood 2002, 101: 1591-1595. PMID: 12393546, DOI: 10.1182/blood-2002-06-1843.
Lymphangioma of the Renal CapsuleZapzalka D, Krishnamurti L, Manivel J, DiSandro M. Lymphangioma of the Renal Capsule. Journal Of Urology 2002, 168: 220. PMID: 12050546, DOI: 10.1016/s0022-5347(05)64895-1.
Paris‐Trousseau syndrome platelets in a child with Jacobsen's syndromeKrishnamurti L, Neglia J, Nagarajan R, Berry S, Lohr J, Hirsch B, White J. Paris‐Trousseau syndrome platelets in a child with Jacobsen's syndrome. American Journal Of Hematology 2001, 66: 295-299. PMID: 11279643, DOI: 10.1002/ajh.1061.
Bone Marrow Transplantation without Myeloablation for Sickle Cell DiseaseKrishnamurti L, Blazar B, Wagner J. Bone Marrow Transplantation without Myeloablation for Sickle Cell Disease. New England Journal Of Medicine 2001, 344: 68. PMID: 11187121, DOI: 10.1056/nejm200101043440119.
Few Reports of Hemoglobin E/β-Thalassemia in Northeast India: Underdiagnosis or Complete Exclusion of β-Thalassemia by Hemoglobin EKrishnamurti L. Few Reports of Hemoglobin E/β-Thalassemia in Northeast India: Underdiagnosis or Complete Exclusion of β-Thalassemia by Hemoglobin E. Journal Of Pediatric Hematology/Oncology 2000, 22: 558-563. PMID: 11132230, DOI: 10.1097/00043426-200011000-00023.
Treatment of sickle cell disease (SCD) by an allogeneic hematopoietic stem cell transplantation (HSCT) using a non-myeloablative preparative regimenKrishnamurti L, Blazar B, Grossi M, Abel S, Vichinsky E, Lubin B, Wagner J. Treatment of sickle cell disease (SCD) by an allogeneic hematopoietic stem cell transplantation (HSCT) using a non-myeloablative preparative regimen. Journal Of Pediatric Hematology/Oncology 2000, 22: 387. DOI: 10.1097/00043426-200007000-00093.
Recurrence of EBV associated, high-grade, post-transplant lymphoma presenting as acute renal failureLewis V, Dahl J, Braunlin E, Steiner M, Perentesis J, Neglia J, Krishnamurti L. Recurrence of EBV associated, high-grade, post-transplant lymphoma presenting as acute renal failure. Journal Of Pediatric Hematology/Oncology 2000, 22: 378-379. DOI: 10.1097/00043426-200007000-00065.
Paris-Trousseau platelets: a manifestation of Jacobsen syndromeKrishnamurti L, Neglia J, Nagarajan R, Berry S, Hirsch B, Matsunaga A, White J. Paris-Trousseau platelets: a manifestation of Jacobsen syndrome. Journal Of Pediatric Hematology/Oncology 2000, 22: 373. DOI: 10.1097/00043426-200007000-00046.
#432 Danaparoid (orgaran) anti-coagulation of pediatric patients with heparin-induced thrombocytopenia (HIT)Weigel B, Lasky A, Krishnamurti L, Perentesis J, Neglia J, Foker J, Key N, Edson R, Steiner M. #432 Danaparoid (orgaran) anti-coagulation of pediatric patients with heparin-induced thrombocytopenia (HIT). Journal Of Pediatric Hematology/Oncology 1999, 21: 457. DOI: 10.1097/00043426-199909000-00035.
#432 Danaparoid (orgaran) anticoagulation of pediatric patients with heparininduced thrombocytopenia (HIT)Weigel B, Lasky A, Krishnamurti L, Perentesis J, Neglia J, Foker J, Key N, Edson R, Steiner M. #432 Danaparoid (orgaran) anticoagulation of pediatric patients with heparininduced thrombocytopenia (HIT). Journal Of Pediatric Hematology/Oncology 1999, 21: 327. DOI: 10.1097/00043426-199907000-00093.
Homozygous Hemoglobin Constant Spring with Normal Electrophoresis: A Possible Cause for Under‐DiagnosisKRISHNAMURTI L, LITTLE J. Homozygous Hemoglobin Constant Spring with Normal Electrophoresis: A Possible Cause for Under‐Diagnosis. Annals Of The New York Academy Of Sciences 1998, 850: 415-419. PMID: 9668571, DOI: 10.1111/j.1749-6632.1998.tb10508.x.
Coinheritance of α-thalassemia-1 and hemoglobin E/β0-thalassemia: Practical implications for neonatal screening and genetic counselingKrishnamurti L, Chui D, Dallaire M, LeRoy B, Waye J, Perentesis J. Coinheritance of α-thalassemia-1 and hemoglobin E/β0-thalassemia: Practical implications for neonatal screening and genetic counseling. The Journal Of Pediatrics 1998, 132: 863-865. PMID: 9602201, DOI: 10.1016/s0022-3476(98)70319-1.

Clinical Trials

Conditions	Study Title
Brain and Nervous System; Pediatrics	A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
Leukemia, not otherwise specified; Leukemia, other; Pediatrics	A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Leukemia, other; Pediatrics	A Phase 3 Trial Investigating Blinatumomab ( NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
Bones and Joints; Brain and Nervous System; Eye and Orbit; Hodgkin's Lymphoma; Kidney; Leukemia, other; Liver; Lymphoid Leukemia; Myeloid and Monocytic Leukemia; Non-Hodgkin's Lymphoma; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Pediatrics; Small Intestine; Soft Tissue	The Project: Every Child Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Pediatrics	A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy With Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) Plus VINO-CPO Maintenance in Patients With High Risk Rhabdomyosarcoma (HR-RMS)
Pediatrics	A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma (RELATIVITY-069)
Pediatrics	A Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination With Vinblastine for Non-NF1, Non-TSC Patients With Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations

Edit Profile

Lakshmanan Krishnamurti, MD

Contact Information

Patient Care

Research & Publications

Biography

News

Research Summary

Extensive Research Description

Coauthors

Selected Publications

Clinical Trials